The Office for Life Sciences (OLS) has announced the appointment of Kenan Poleo as Director, effective from May 2026.

Kenan succeeds Roz Campion and will lead the cross-government delivery of the UK’s Life Sciences Sector Plan, which forms part of the Government’s Industrial Strategy. The role also includes responsibility for innovation priorities linked to the 10 Year Health Plan.

Reporting jointly into the Department for Science, Innovation and Technology (DSIT), the Department of Health and Social Care (DHSC), and the Department for Business and Trade (DBT), the Director works closely with OLS Executive Chair Steve Bates OBE to support the Government’s ambition for the UK to become the world’s third most important life sciences economy by 2035.

Kenan brings extensive experience from across government, healthcare, and international trade. Most recently, Kenan served as Consul General and Trade Commissioner for Eastern Europe and Central Asia. Prior to this, Kenan held senior trade and innovation roles including Her Majesty’s Deputy Trade Commissioner for Europe and Head of Global at Innovate UK.

Kenan’s earlier career included a range of senior UK Government positions focused on manufacturing strategy, energy, and environmental legislation, and the chemicals industry. Before entering government service, Kenan worked within the NHS, commissioning services related to sexual health, HIV/AIDS, refugee and homelessness health, and support for Black and Minority Ethnic communities.

BHTA members may wish to note the appointment given the Office for Life Sciences’ ongoing role in shaping healthcare innovation, regulation, and industry collaboration across the UK.

Members wishing to contact the Office for Life Sciences can do so via: Director.OLS@officeforlifesciences.gov.uk

The British Healthcare Trades Association (BHTA) has produced a new report analysing product spend within the NHS Supply Chain Framework for Artificial Limb Components and Associated Products. This information is exclusively available to BHTA members.

The report has been made possible through a Freedom of Information (FOI) request submitted by the BHTA to NHS Supply Chain, giving members valuable visibility into NHS procurement activity that is not routinely available.

Covering the period 23 November 2024 to 21 November 2025, the report provides an overview of product spend, usage, monthly activity, and purchasing patterns across the prosthetics framework.

The findings offer members a useful opportunity to better understand procurement trends and market dynamics within the prosthetics sector, supporting informed strategic decision-making.

Members of the Prosthetics and Orthotic Section can download the full report here.

The BHTA Retailers’ Day 2026 brought together mobility and assistive technology retailers from across the UK for a focused day of learning, collaboration, and industry insight. Held on 22 April in Northampton, the event was designed to equip retailers with practical guidance, expert perspectives, and the latest updates to support their businesses and the customers they serve.

The day also included a focused AI panel discussion, exploring how artificial intelligence is beginning to influence mobility and independent living retail, which we have covered in a separate article.

This article highlights the engaging presentations delivered throughout the day. Each session offered valuable takeaways, from improving customer experience, and marketing strategies to navigating regulatory changes and enhancing accessibility across the retail journey.

A line-up of expert speakers

The day featured a strong programme of speakers, each bringing specialist knowledge and real-world experience to the challenges and opportunities facing healthcare retailers today.

Clare Bailey, the founder of The Retail Champion, delivered the keynote session, sharing insights on how retailers can stand out and thrive in an increasingly competitive and customer-driven market.

Jolie and Imali from Inkfire explored how retailers can approach social media more effectively, focusing on choosing the right platforms, and embedding accessibility into digital communications.

Mark Crane, Partner at Addleshaw Goddard, led a session on consumer law compliance, outlining key regulatory developments and what they mean for retailers in practice.

Cath Cashman from the Research Institute for Disabled Consumers (RiDC) presented on designing an accessible retail journey, drawing on extensive research to highlight barriers and opportunities across both online and in-store experiences.

Standing out in healthcare retail

Clare Bailey’s keynote challenged retailers to raise the bar on customer experience, emphasising that being ‘good’ is no longer enough as expectations rise and customers have more choice.

A core message was the emotional context of healthcare retail: customers are often making difficult, unexpected decisions and are seeking reassurance, not just products. Every touchpoint matters, and the experience does not stop at the till. Websites, phone calls, delivery, and aftercare are all part of one connected journey.

Clare highlighted a common disconnect: retailers sell independence, confidence, and quality of life, but the experience can feel clinical or transactional, requiring a more human and consistent approach.

What makes retailers stand out

• Prioritise clarity over complexity: too much choice can overwhelm customers, and simple communication builds confidence
• Be consistent across all channels so customers experience one coherent brand
• Use digital to support in-store, reduce anxiety, and build trust before a visit

Practical actions for retailers

• Review your store with fresh eyes: is it easy to navigate, welcoming, and designed for conversation?
• Create clearer zones, improve lighting, and provide space for private discussions
• Invest in staff training so teams can handle sensitive conversations, listen well, and help customers feel understood, supported, and in control

Rethinking social media and digital communication

Inkfire’s session offered a refreshing perspective on social media, encouraging retailers to focus less on doing more and more on doing what matters.

A central message was that social media is fundamentally about communication, not performance. Rather than trying to be present on every platform or chasing trends, retailers should prioritise the channels that best align with their audience, capacity, and goals.

Where to focus and why

• Instagram supports visual storytelling
• Facebook helps build community and retention
• LinkedIn builds authority and partnerships
• TikTok/Reels aid discovery but are not essential
• Email remains a high-conversion channel you own

Accessibility was a major theme throughout the session. With disabled spending power, often referred to as the purple pound, worth £274 billion annually, ensuring content is accessible is not only the right thing to do, but also a clear business opportunity. Practical steps such as using alt text, captions, clear formatting, and readable design can make a meaningful difference.

The speakers also highlighted the importance of trust and consistency. Success on social media is less about likes and views, and more about meaningful engagement – such as enquiries, messages, and clicks. Ultimately, content should help customers feel confident in choosing a retailer.

Understanding consumer law and compliance

Mark Crane’s session provided retailers with a clear overview of the evolving consumer law landscape, with a particular focus on the Digital Markets, Competition and Consumers Act 2024.

The session highlighted the increasing enforcement powers available to regulators, including the ability to impose significant fines and sanctions for non-compliance. This reinforces the importance of ensuring that all aspects of a retail business – from pricing, and promotions to customer communications – meet legal requirements.

Key areas of focus included unfair commercial practices, fake reviews, subscription models, pricing transparency, and product claims. Mark explained that claims suggesting a product, service, brand, or business is better for the environment or health must be truthful, clear, fair, meaningful, and backed by evidence. For example, practices such as ‘drip pricing’, misleading promotions, or unsubstantiated claims can expose businesses to risk if not handled correctly.

Mark also highlighted the importance of taking a holistic approach to compliance across the customer journey, ensuring each stage is clear, fair, and transparent.

Retailers can also refer to the BHTA’s Pricing Practices and Price Transparency policy advice note, produced in association with Addleshaw Goddard, for further support on keeping pricing clear, fair, and compliant.

Designing an accessible retail journey

Cath Cashman’s presentation drew on RiDC’s Re-imagining Retail research, based on 955 survey responses, alongside interviews and a disabled steering group, to understand barriers and improve accessibility across the retail journey.

The research found that 98 percent of disabled people who shop in-store face barriers, one in two regularly abandon shops due to inaccessibility, and 67 percent experience difficulties navigating aisles. Accessibility issues can occur at every stage of the journey, from finding information online to navigating stores and completing purchases.

The session emphasised that the retail journey begins before a customer even leaves their home, with many needing clear information to plan visits, or deciding not to visit at all without it.

In-store, practical improvements such as step-free access, wider aisles, clear signage, seating areas, and accessible facilities can significantly improve the experience. Staff training and awareness are equally important, ensuring that teams are equipped to provide appropriate support and assistance.

Improving accessibility includes ensuring step-free access, clear layouts, accessible facilities, trained staff, and strong communication of accessibility information online.

On 22 April 2026, industry professionals gathered in Northampton for the BHTA Retailers’ Day, a focused event for mobility and assistive technology retailers.

Titled ‘AI in Mobility and Independent Living Retail – Practical Tools Without Losing the Human Touch’, and led by Clare Bailey from The Retail Champion, the panel brought together:

• David Stockdale, Chief Executive of the BHTA
• Alastair Gibbs from TPG DisableAids
• Martyn Sibley from Purple Goat
• Steve Sydee from Smart Impact

The discussion centred on how AI can be used in practical ways without losing the trust, empathy, and personalised service that define the sector.

From fear to practical adoption

Retailers are moving from fear, to curiosity, to adoption. In many cases, AI is already being used informally. As David noted, bringing that usage into the open is often the first step towards using it effectively.

Panellists framed AI as an enabler. The focus was on starting small, testing low-risk tasks, and building confidence over time. This was described as a change management process, requiring internal buy-in and clear direction.

Clare Bailey encouraged a simple starting point: use AI to capture ideas, structure thoughts, or draft content. These small wins quickly demonstrate value.

Martyn Sibley added a lived-experience perspective, explaining how AI has helped him overcome dexterity challenges and improve productivity, highlighting its role as both a business and accessibility tool.

Where AI is already adding value

AI’s strongest impact is in improving efficiency, consistency, and quality by reducing routine admin work. Common uses include drafting content, summarising information, automating repetitive tasks, and supporting research and scheduling.

David explained that within the BHTA, this has freed up time to reinvest into member engagement and face-to-face activity.

Steve emphasised that success should be judged by outcomes: if customers experience faster, more relevant service, AI is working. If they notice the AI itself, something has gone wrong.

Preserving the human touch

Human interaction remains central in mobility and independent living retail. AI cannot replicate empathy, judgement, or relationship-building, and these remain key differentiators.

Instead, AI should support staff by handling routine work and enabling more meaningful customer interactions.

The panel also raised the risk of over-automation. If time saved is not reinvested, or if technology removes valuable human experiences, it can have negative consequences.

Alastair stressed the importance of understanding customer comfort levels. Some customers will embrace automation, while others may find it unsettling. Retailers must judge where technology adds value and where the human touch remains essential.

Enhancing the customer journey

AI can support the entire customer journey, from discovery to aftercare.

In marketing, the shift from traditional SEO to AI-driven search is significant. Retailers must consider how their content appears in tools like ChatGPT, not just Google. This increases the importance of high-quality, informative content that answers real customer questions.

Long-form, story-led content and strong brand identity were highlighted as key. As AI increasingly mediates recommendations, trusted brands are more likely to be surfaced.

Accuracy is also critical. AI outputs reflect the information available online, meaning retailers must ensure their content is consistent and up to date. Poor or generic AI-generated content can damage credibility, as customers can often recognise it.

AI also enables more personalised engagement. As Martyn noted: “I think the benefit with AI is we can understand what large swathes of consumers need and want and provide more bespoke service.” However, this should support conversations, not replace them.

In aftercare, AI is already being used to improve responsiveness. Alastair described how AI-driven triage systems can resolve many support queries, particularly outside working hours, allowing staff to focus on more complex cases.

The importance of education and strategy

Education is essential for effective adoption. Retailers were encouraged to set aside time to learn, experiment, and build internal knowledge.

Alastair highlighted support options such as local growth hubs, Innovate UK funding, and Knowledge Transfer Partnerships, which can help fund both technology and learning.

The panel also noted that AI is evolving rapidly, and different tools have different strengths. Retailers should focus on understanding where each tool adds value, rather than adopting technology for its own sake.

Risks and considerations

While the outlook was positive, several risks were highlighted:

• Poor implementation can damage trust and authenticity
• Automation raises questions around data and control
• Overuse can reduce service quality
• Not all customers are comfortable with advanced technology
• Failing to engage with AI risks falling behind

Practical starting points for retailers

For retailers starting out with AI, the advice was simple: begin with low-risk tasks, test and refine outputs, and expand gradually. Maintain oversight, focus on quality, and use AI to support – not replace – what people do best.

The overall sentiment of the panel was that when used thoughtfully, AI can free up time, improve service, and strengthen the human elements that matter most.

The author used AI to help prepare this article.

The British Healthcare Trades Association (BHTA) has produced a new report analysing product spend within the NHS Supply Chain Framework for Orthotics, Podiatry and Immobilisation. This information is exclusively available to BHTA members.

This insight has been made possible through a Freedom of Information (FOI) request submitted by the BHTA, providing members with valuable visibility into NHS procurement activity that is not routinely available.

Covering the first full year of the framework (March 2025 – March 2026), the report highlights key trends in spend, product usage, and demand across the sector. It provides a detailed breakdown of where NHS expenditure is concentrated, alongside insights into high-volume product categories and purchasing patterns.

The findings offer members a unique opportunity to better understand market dynamics, identify areas of demand, and support informed strategic decision-making within the orthotics and prosthetics sector.

The BHTA is also exploring opportunities to obtain similar data for the prosthetics framework and will look to secure comparable insights from other framework providers, further strengthening the support available to members.

Members of the Prosthetics and Orthotic Section can download the full report here.

BHTA members are invited to contribute to a new industry survey exploring the barriers to developing health technologies for children.

According to the NIHR HealthTech Research Centre in Paediatrics and Child Health and Innovate UK Business Connect, medical technology continues to transform adult healthcare. However, progress within paediatric healthcare has not kept pace.

Despite children representing around 20 percent of the UK population, relatively few technologies are designed specifically for paediatric use. This highlights a wider, systemic challenge across the sector.

To better understand these issues, a short, confidential survey has been launched for organisations working in medical technology and health innovation.

The survey asks whether organisations have considered entering the child health sector and invites respondents to rate key barriers, including regulatory requirements, funding availability, clinical trial complexity, and access to paediatric expertise. It also explores challenges such as scaling technologies, co-designing with children and young people, and the commercial viability of the sector.

Insights gathered will help inform engagement with policymakers, investors, and industry partners, supporting future strategy for paediatric health innovation.

The survey takes approximately 10–15 minutes to complete and is open to all medtech organisations. Responses will be treated confidentially and anonymised in any published outputs.

A summary of findings is expected in summer 2026, followed by a programme of events to address the most commonly reported barriers.

The BHTA encourages its members to take part and share their expertise to help shape a more inclusive healthcare technology landscape.

Complete the survey here.

Deadline: 15 April 2026

NHS Supply Chain (NHSSC) has issued an update on the potential impact of ongoing geopolitical disruption in the Middle East, saying it is taking proactive steps to protect product availability and maintain continuity of supply.

NHSSC said the situation has increased the risk of disruption for suppliers with facilities or commodity dependencies in the region. It also noted an ongoing cost risk linked to core commodity pricing, as well as knock-on effects for other components and materials.

The organisation said a coordinated, intelligence-led response has been underway across its supply chain, resilience, and category teams. This has included a focused review of suppliers with upstream facilities in the Middle East, with identified suppliers contacted directly for assurances on continuity plans, logistics routes, and any emerging constraints.

NHSSC also said it has used risk analytics data to identify suppliers with elevated cyber-risk profiles. These suppliers have been contacted to confirm the cyber protection measures they have in place and to provide reassurance that there is no onward threat to NHS systems or supply continuity.

In addition, teams are carrying out continuous horizon scanning to identify early indicators of disruption, including transport route instability and cyber threat activity, with insights shared across operational teams to support rapid decision-making and prioritisation. Commodity-level forecasting is also being used to identify products of concern and anticipate potential shortages; where appropriate, stockholding has been increased to build resilience and maintain continuity of supply.

BHTA resources for members on Middle East disruption

For BHTA members, the position remains one of close monitoring rather than immediate widespread disruption. The BHTA has produced a member-only update on UK business supply chain disruption in the Middle East, which members can access for further context on current developments.

The BHTA has also published member-only fuel resilience and continuity planning guidance, signposting practical considerations for businesses reviewing their resilience planning.

The BHTA will continue to monitor developments relevant to the healthcare and assistive technology sector and share further updates where useful.

The Department of Health and Social Care (DHSC) is developing a new initiative known as the MedTech Compass, designed to support more effective and consistent procurement decisions across the NHS. While still in development, the MedTech Compass represents a move towards a more streamlined, value-focused approach to how medical technologies are assessed and adopted.

Here’s what BHTA members need to know about the MedTech Compass.

What is the MedTech Compass?

At its core, the MedTech Compass is intended to enable smarter procurement decisions by allowing NHS organisations to compare products side by side based on value rather than price alone. It is designed so that a single set of supplier data can be submitted once and reused across multiple procurement processes.

This approach aims to support more consistent and transparent decision-making, reduce duplication across NHS procurement, and improve efficiency for both suppliers and buyers. The MedTech Compass has been described as a comparison-style tool, intended to support procurement teams and clinicians in making more informed choices.

When is the MedTech Compass expected to be introduced?

The MedTech Compass is currently progressing through its development phases. The programme began with a discovery phase to assess user needs and market challenges. This has been followed by the alpha phase (November 2025 to March 2026), where concepts are being tested through a prototype. A beta phase is expected during the 2026/27 financial year to build and test the full system, followed by a live service rollout across the NHS in 2027/28.

The alpha phase has recently passed a Government Digital Service assessment with a Green rating. DHSC is expected to progress to procurement for the beta phase through an Invitation to Tender, with the beta likely to begin in summer 2026 and run for approximately 12 months.

What will the MedTech Compass mean for suppliers?

For suppliers, the MedTech Compass has the potential to reduce administrative burden and simplify engagement with NHS procurement.

By enabling a “submit once, use many times” approach to data, it should reduce the need to repeatedly provide the same information across different procurement exercises, improve clarity around requirements, and support more predictable and consistent evaluation criteria.

At the same time, suppliers will need to ensure that their product data is comprehensive, accurate, and aligned with the value-based metrics the MedTech Compass is expected to prioritise.

How will the MedTech Compass be used?

The MedTech Compass is intended to support NHS procurement teams and clinicians by providing a structured way to assess and compare technologies.

Rather than focusing solely on price, the system is expected to incorporate a broader definition of value, including factors such as clinical outcomes, system efficiency, and wider benefits to the healthcare system.

By standardising how information is presented and assessed, the MedTech Compass aims to reduce variation across organisations and support faster, more consistent decision-making.

For additional context on wider medtech policy developments, members can read our previous article on the MedTech Strategy and DHSC initiatives.

The April 2026 NHSSC (NHSSC) supplier webinar highlighted several important developments for suppliers, with a particular focus on cyber resilience requirements, supplier processes, and upcoming engagement expectations. Below is a summary of the key updates for BHTA members.

NHS cyber resilience expectations

Presented by Liam Donaghy and Hannah Shelton (NHS England), this session focused on the increasing importance of cyber security across the health and social care system.

Suppliers are a critical part of the NHS supply chain and are increasingly being targeted as a potential route into the wider system. As cyber threats grow in frequency and sophistication, there is a stronger expectation for suppliers to take an active role in protecting systems and services.

The NHS Cyber Improvement Programme is a national initiative designed to strengthen cyber resilience across health and social care. See the slide below for more information on the programme.

A key development is the next phase of cyber engagement, including the Third-Party Risk Management (TPRM) remediation process. This follows a national open letter to suppliers and signals increased engagement across the sector.

Suppliers can expect engagement on key cyber security controls, requests for supporting evidence where appropriate, and a more coordinated, risk-based approach to assurance. There will also be a continued effort to reduce duplicated requests across NHS organisations.

Suppliers are encouraged to review requirements such as the Cyber Security Supply Chain Charter and prepare for upcoming engagement.

Suppliers can also engage with the programme through webinars, consultations, and pilot activities. For further information or queries, suppliers can contact: england.cyberimprovement@nhs.net

Supplier escalation and contact readiness programme

Presented by Lisa Harmsworth, this session highlighted the importance of maintaining accurate supplier contact information.

NHSSC has identified that supplier contact data is not always up to date, which can impact communication and delay issue resolution. To address this, a structured approach to contact management is being introduced.

Five core supplier contact categories are being established to support effective communication and escalation. See the slide below for further details.

Suppliers will be contacted in the coming months to verify and update their contact details. There is an expectation that suppliers will provide accurate contact information, notify NHSSC of any internal staff changes, and regularly review and confirm contact details.

Maintaining accurate contact data will support more efficient communication, clearer escalation processes, and improved supply chain resilience.

Novation: what suppliers need to know

Presented by Steph Holmes-Fletcher, this session outlined NHSSC’s policy on supplier novation.

Supplier novation refers to changes in how framework agreements, contracts, or awarded lots are transferred between suppliers under NHSSC (Supply Chain Coordination Limited (SCCL)) arrangements.

The slide below explains SCCL’s novation policy.

NHS Core List: brief update

Presented by Hamish Makanji, NHSSC provided a brief update on the NHS Core List.

The NHS Core List is a broader NHS initiative, being implemented by NHSSC, which aims to standardise commonly used products and reduce unwarranted variation across the system.

The programme continues to develop, with a pipeline of product categories under review and ongoing engagement planned with suppliers once this pipeline is established.

Suppliers can share suggestions or feedback on NHS Core List opportunities by contacting CoreList@supplychain.nhs.uk.

For a more detailed overview of the NHS Core List and its implications, see our previous article.

Key takeaways for suppliers

• Prepare for increased cyber security engagement and assurance requirements
• Ensure supplier contact details are accurate and regularly updated
• Understand how supplier novation may affect your framework agreements
• Engage with NHS initiatives, including providing feedback on the NHS Core List

BHTA will continue to monitor developments from NHSSC and share relevant updates with members.

Written by the BHTA’s Bill Lee, Head of Policy and Compliance, and Sarah Sarsby, Communications Manager. The authors used AI to help prepare this article.

The British Healthcare Trades Association (BHTA) has published its BHTA Manifesto Policy Update 2026, building on the 2023–24 Manifesto to reflect both sector progress and a rapidly evolving health and social care landscape.

First launched in Parliament, the original Manifesto set out five key areas requiring government attention, centred on stronger collaboration between industry, policymakers and healthcare professionals. Since then, BHTA has seen its “Five Rs” begin to translate into action across government and key stakeholders including DBT, DHSC, MHRA, NHS, NHSE and NICE.

The BHTA Manifesto Policy Update 2026 sharpens this momentum into delivery, setting out five clear priority areas:

1. Release NHS Capacity – Industry Partnership for Effective H&SC Delivery
2. Regulate for Safe, Effective UK Medical Devices
3. Rethink Innovation Adoption & Procurement
4. Regularise Sustainability & Social Value
5. Reduce Export Barriers

Together, these priorities form a practical roadmap for how industry and the NHS can work in partnership to deliver better outcomes, faster innovation, and a more sustainable system.

Why the update matters

The BHTA Manifesto Policy Update 2026 provides clarity for BHTA members navigating an increasingly complex policy environment, highlighting where industry can lead, from enabling community-based care to supporting innovation uptake and responding to regulatory change. At the same time, it reinforces to government and the NHS the value of working in partnership with a trusted, ethical healthtech sector to improve outcomes and system efficiency.

A perspective from industry: Bob Russell

To explore the implications of the BHTA Manifesto Policy Update 2026 through a government affairs lens, the BHTA spoke to Bob Russell, Market Access and Government Affairs Director, UK at Hollister, and a member of the BHTA Board.

When asked which of the five key policy areas in the BHTA Manifesto Policy Update 2026 is most important, Bob highlighted partnership and prevention:

“In particular Freeing NHS Capacity through Partnership and Prevention – this recognises the vital role that we, and indeed all BHTA members, can play in supporting the NHS 10 Year Plan and working in true partnership to give better user outcomes”

He emphasised that, if progress could only be made in one area of the five areas of the manifesto, this would be the most impactful for the sector as a whole:

“I think that it as above – this to me is fundamental to achieve. For many years, the concept of partnerships has been talked about but not necessarily implemented to its fullest extent. I believe we are now in an environment where those partnerships will become increasingly important and meaningful as BHTA members help the NHS meet its 10 Year Plan.”

Looking ahead, Bob also pointed to the importance of staying ahead of regulatory developments:

“I think navigating the evolving regulatory environment successfully will be key. Recently announced legislative changes and factor such as ongoing MHRA consultations mean that BHTA members will need to keep very informed as to any potential impacts.”

He concluded by recognising the strength of the updated manifesto and its role in shaping future dialogue:

“The BHTA Manifesto Policy Update 2026 is a very comprehensive document, and I believe focuses on the key areas that are important to members. I am pleased to see the impact of the original 2023-24 Manifesto themes and the dialogue it has opened with key stakeholders. This update advances those themes in a significant fashion through setting clear priorities and actions.”

Looking ahead

The BHTA Manifesto Policy Update 2026 sets out a clear roadmap for how industry, government and the NHS can work together to deliver better outcomes, accelerate innovation and build a more sustainable health system.

Read the full BHTA Manifesto Policy Update 2026 to explore the priorities and actions in detail and understand how the sector can help shape the future of UK healthtech.

Over 30 British Healthcare Trades Association (BHTA) members attended this year’s Naidex, showcasing a wide range of exciting and innovative products and services. BHTA members reported very positive feedback from customers at the show, enjoyed speaking to people face-to-face, and connected with new and familiar faces.

From commercial insurance for businesses and a National Mobility Equipment Register to award-winning powerchairs and single grip hands, Naidex 2026 proved a successful event for members. Here’s what they had to say about the event:

---

---

---

Cyber security remains a growing concern for UK organisations, particularly those operating within healthcare and associated supply chains. Insights from a recent webinar hosted by the Department of Health and Social Care (DHSC) and the National Cyber Security Centre (NCSC) highlight both the scale of current threats and the practical steps organisations can take to protect themselves.

The current cyber threat landscape

The most significant threat facing UK businesses today is ransomware. However, ransomware attacks are rarely isolated incidents—they are typically enabled by common vulnerabilities and everyday behaviours within organisations.

Three of the most frequent entry points for attackers are:

• Phishing: Malicious links in emails, fraudulent messages on platforms such as WhatsApp, and increasingly sophisticated tactics such as AI-generated deepfakes.
• Social engineering: Attackers impersonating IT staff or trusted services to trick employees into sharing sensitive information or resetting passwords.
• Unpatched vulnerabilities: Outdated systems or unresolved security gaps—sometimes years old—that can be exploited to bypass defences.

Other common threats include denial-of-service attacks, spam, and business email compromise.

While threat actors may include state-sponsored groups or independent criminals, the distinction between them is increasingly blurred. Key state actors of concern include Russia, China, Iran, and North Korea. However, for organisations affected by an attack, attribution is often less important—the priority is restoring systems and minimising disruption.

Why healthcare and supply chains are targeted

The healthcare sector is a particularly attractive target for cyber attackers due to:

• Access to highly sensitive and valuable data, including patient information and intellectual property
• Financial incentives, as organisations may feel pressure to pay ransomware demands
• Links to high-value goods, such as pharmaceuticals

Cyber incidents can have serious operational and financial consequences. In severe cases, attacks can threaten the viability of entire businesses and lead to prolonged recovery periods.

Supply chains are also increasingly targeted. Attackers often focus on smaller organisations within a supply chain, where protections may be weaker. Once compromised, these organisations can act as a gateway to larger, more secure entities. Many supply chain breaches stem from basic weaknesses, particularly phishing attacks.

Strengthening supply chain security

Managing supply chain risk has become a critical priority. In recent years, many organisations have struggled due to suppliers not fully understanding cyber security risks, a lack of effective tools to evaluate supplier security, and limited visibility across supply chains.

To address this, there is a growing expectation—particularly among larger organisations—that suppliers demonstrate strong cyber security credentials. The Cyber Essentials scheme is now widely recognised as a baseline standard and is increasingly required by the NCSC and the Department for Science, Innovation and Technology (DSIT) across large organisations’ supply chains.

The NCSC’s Cyber Essentials Supply Chain Playbook is a valuable resource that helps organisations assess supplier risk, improve visibility across supply chains, and set appropriate security requirements for partners.

Practical steps organisations can take

Improving cyber security does not need to be complex or costly. The NCSC emphasises that many effective measures are straightforward to implement.

Key actions include:

• Establish strong governance: Use tools such as the NCSC Board Toolkit and Cyber Code of Practice to ensure cyber security is addressed at leadership level.
• Sign up to the NCSC Early Warning service: All organisations should sign up to this free service, which alerts organisations to suspicious activity and helps prevent attacks before they escalate.
• Use the Cyber Action Toolkit: This provides clear, practical guidance on improving cyber resilience.
• Achieve Cyber Essentials certification: This demonstrates a recognised level of security and is increasingly required across supply chains. Organisations can begin by using the Cyber Essentials Supplier Check tool.

Preparing for cyber incidents

Preparation is critical to minimising the impact of an attack. Organisations should develop a clear incident response plan, recognising that the first 24 hours of an incident are particularly crucial for an effective response.

This should include ensuring staff understand their roles and responsibilities, planning how to communicate during an incident (especially if systems such as email are unavailable), and regularly testing response plans using tools such as NCSC’s Exercise in a Box.

Testing and refining these plans are essential to ensure they remain effective.

Additional free cyber security resources

Further guidance and support is available from a range of UK government and cyber security organisations, including the NCSC website, which hosts all tools and guidance, as well as government guidance such as the ministerial letter to large organisations and the ministerial letter to small organisations.

For additional support on supply chain cyber security, organisations can contact: supplychain@iasme.co.uk

Taking action now

Cyber threats continue to evolve, but the steps needed to improve resilience are well understood and accessible. By using the guidance and tools available, BHTA members can significantly reduce their risk and strengthen their overall cyber security posture.

Members are encouraged to review the resources referenced throughout this article and take proactive steps to ensure their organisations are prepared.

BHTA members involved in NHS tenders are encouraged to take part in a Department of Health and Social Care (DHSC) industry readiness survey on value-based procurement (VBP).

This survey provides an opportunity for companies across the health technology sector to share their perspectives and help shape how VBP is implemented across the NHS in England.

Why this matters

Value-based procurement shifts the focus from reducing product costs to delivering better outcomes and lowering total costs across the patient pathway.

NHS Supply Chain is working with the NHS and industry to apply this approach in practice, aiming to improve efficiency, reduce waste, and deliver measurable benefits such as increased productivity, reduced infection rates, and improved patient outcomes.

The approach also supports closer collaboration between suppliers, procurement teams, and healthcare providers, with a focus on delivering long-term value to the health system.

More information on VBP can be found in this BHTA article.

About the survey

DHSC has developed national VBP standard guidance, currently being piloted by 13 NHS Trusts, with publication expected in summer 2026.

The survey has been designed to assess industry readiness and understand organisational attitudes towards VBP. Findings will inform DHSC’s implementation plans and support the transition to value-based approaches across the NHS.

It asks organisations to provide:

• Company and sector information
• Levels of awareness of VBP and the guidance
• Current preparedness and actions being taken
• Views on support needed from government
• Perspectives on key success factors
• Additional feedback to inform policy development

Responses are confidential and will not be shared with third parties.

Complete the survey

• Time to complete: approximately 10 minutes
• Response requirement: one response per company
• Deadline: 5pm on 27 March

Relevant members are encouraged to submit a response before the deadline via the value-based procurement survey.

Members involved in NHS tenders or expecting to be impacted by changes to procurement frameworks are particularly encouraged to participate.

MPs have urged the government to consider a national strategy for disability equipment provision after a Westminster Hall debate highlighted delays in wheelchair services, shortages in housing adaptations, and inconsistent access to assistive equipment across the UK.

Opening the debate, Seamus Logan MP said disability equipment plays a crucial role in supporting independence and quality of life for millions of people.

“Around 25% of the UK population are disabled,” Seamus said ahead of the debate. “The provision of disability equipment is of paramount importance to many across the UK. When provided, it can significantly improve quality of life and independence.”

Seamus said the debate would focus particularly on wheelchair provision, housing adaptations, and wider barriers disabled people face when trying to access equipment that enables everyday living.

Watch the full debate here.

Delays and inconsistent provision

Several MPs used the debate to highlight long waiting times and uneven access to equipment depending on where people live.

John Hayes MP pointed to NHS England data suggesting that around 70% of wheelchair users wait more than three months for equipment, while roughly 30% wait longer than six months, and around 15% more than a year.

MPs argued that these delays can significantly affect independence, employment, and daily life for disabled people.

Jim Shannon MP said that while appropriate equipment can transform lives, many people with complex needs are waiting too long to receive it. In some cases, Jim noted, individuals have resorted to crowdfunding to obtain suitable wheelchairs.

Helen Maguire MP highlighted wider structural pressures affecting services, including staffing shortages, supply chain issues, and variation in local authority processes, which Helen said were contributing to delays and inconsistent provision.

Calls for a national strategy

Daniel Francis MP, chair of the All-Party Parliamentary Group (APPG) for Access to Disability Equipment, argued that the current system is fragmented and lacks clear national direction.

Drawing on findings from the APPG inquiry (see the full report: APPG for Access to Disability Equipment report), Daniel said the collapse of major supplier NRS Healthcare had exposed weaknesses in the current model of provision.

Daniel and other MPs called for the government to consider introducing a national strategy for community equipment to improve oversight, strengthen accountability, and ensure more consistent access for disabled people.

Housing adaptations and accessible homes

Housing adaptations were also raised as a significant challenge during the debate. MPs pointed to shortages of adapted housing, long waits for assessments, and cases where people were told necessary adaptations could not be carried out.

Some contributors warned that even when adaptations are delivered, they are not always designed in ways that genuinely improve independence and quality of life.

Government response

Responding for the Government, Social Care Minister Dr Zubir Ahmed acknowledged that some wheelchair services are underperforming and that waiting times in parts of the system remain too long.

However, he defended the current structure in England, where integrated care boards commission services to meet local health needs, while local authorities hold statutory duties for providing community equipment in the home.

The minister said NHS planning guidance already requires integrated care boards to reduce waiting times for wheelchair services, with performance monitoring due to be strengthened from 2026–27.

He also pointed to increased use of Personal Health Budgets, and confirmed that £723 million in Disabled Facilities Grant funding would be available in 2026–27 to support housing adaptations.

While he stopped short of committing to a national strategy, the minister said he would write to colleagues responsible for disability policy and quality frameworks to share concerns raised during the debate.

Sector implications

The debate underscored growing concern across Parliament about delays, fragmentation, and accountability in disability equipment provision.

For the sector, the discussion signals increasing political attention on the need for more coordinated planning, improved procurement resilience, and better access to assistive technology that enables disabled people to live independently.

The British Healthcare Trades Association (BHTA) is aware of a Field Safety Notice issued by BHTA member company Arjo concerning certain Tenor patient lifts.

This article shares important safety information for healthcare professionals, clinical staff, and facilities that use or manage the affected devices.

What has been identified?

Arjo has identified a potential issue affecting the lifting actuator used in certain Arjo Tenor lifts, as well as certain spare part actuators (TEN.107 and RKT.560).

During internal product testing at Arjo’s manufacturing site, an anomaly was detected in the behaviour of the lifting actuator. Further investigation confirmed that an internal component supplied by a third-party manufacturer may not meet the required mechanical strength specifications.

In rare circumstances, this could result in the actuator losing its ability to hold the load and cause a rapid, uncontrolled downward movement of the lifting arm.

The issue cannot be detected during normal pre‑use checks and would only become apparent if the component were to fail.

What is the potential risk?

If an affected actuator were to fail during use, the lifting arm could move downwards unexpectedly. This may expose patients and caregivers to potential injury.

Potential outcomes include falls, head injury, or other serious trauma for patients being lifted. Caregivers in close proximity to the device could also be at risk of musculoskeletal injuries, such as sprains, fractures, or other physical injuries.

Arjo has confirmed that no incidents or adverse events have been reported, and the issue was identified through internal testing.

Which devices are affected?

The Field Safety Notice applies to specific Arjo Tenor lifts manufactured between 6 March 2025 and 28 November 2025, along with certain spare part actuators.

Affected units can be identified by their serial number, which is located on the right-hand side of the lift mast.

Healthcare facilities and service providers should check the serial number on each device against the list of affected units provided by Arjo or a local Arjo representative.

What actions are required?

Arjo has instructed that all potentially affected Tenor lifts must be removed from service immediately and must not be used until the corrective action has been completed.

Healthcare facilities and organisations with potentially affected devices should:

• Identify any affected Tenor lifts using the serial number information provided by Arjo
• Remove affected devices from use immediately
• Inform relevant staff within the facility about the Field Safety Notice
• Complete and return the Customer Response Form provided by Arjo
• Ensure the devices are available for service when Arjo schedules the corrective action visit

If a Tenor lift has been transferred or sold to another facility, this information should be included in the response form so that the affected device can be traced and corrected.

Corrective action

Arjo will carry out a Field Safety Corrective Action consisting of the replacement of the affected lifting actuator with an updated component that meets the required mechanical specifications.

The actuator replacement will be carried out free of charge by Arjo service personnel, restoring the device to safe operating condition.

Until the actuator has been replaced, affected lifts must remain out of service. The devices do not need to be returned or destroyed, as the corrective action will be performed on-site.

Further information

Healthcare professionals and facilities are encouraged to review the official Field Safety Notice on the MHRA website for full details, including the list of affected serial numbers and response instructions.

For further information regarding this Field Safety Notice or assistance with the corrective action, healthcare providers should contact their local Arjo representative.

This communication is intended to ensure that BHTA members, healthcare professionals, and device users are aware of the manufacturer’s corrective action and the steps required to support continued patient and caregiver safety.

NHS Supply Chain’s March 2026 supplier webinar included a number of updates for suppliers, but two are particularly important for BHTA members: changes to the Economic and Financial Standing (EFS) guidance note, and clarification around distributor and subcontractor arrangements.

Economic and Financial Standing update

On EFS, NHS Supply Chain said the government guidance note on Economic and Financial Standing was updated on 31 December 2025, with NHSSC revising its own approach in response. NHSSC said the underlying methodology was first introduced through Procurement Policy Note guidance in 2023, later embedded into the Procurement Act 2023, and has been reflected in its Invitation to Tender documentation since spring 2024.

NHSSC said it uses EFS to assess suppliers’ overall risk rating by testing and scoring five key financial ratios alongside a Dun & Bradstreet Failure Score, using the bronze scale. It said this is not a pass/fail measure for general award, but a contract management and risk tool. However, NHSSC noted that a supplier rated High, its highest level of concern, could still be excluded from mini competitions held after a general award.

NHSSC also said customers can ask to see a supplier’s EFS rating as part of their due diligence. Suppliers that are concerned about receiving a low score, or know they typically score red against some financial characteristics, can speak to NHSSC in advance through their Category Manager, provided this happens before they are in tender.

The main change is that the updated guidance now explicitly applies to framework-based awards. NHSSC said it will continue using the same tests as before, but with updated parameters, and the new ratios are set out in the revised guidance note. Suppliers can compare the old and new versions side by side to understand what has changed.

NHSSC said it will not amend its documentation or testing before 1 April 2026. It described the revised thresholds as generally tighter for the strongest ratings, while also saying that the changes appear limited in practice. Based on a broad sample of more than 500 current suppliers, fewer than 20 saw a change in their overall rating, with as many ratings improving as worsening.

Distributor and subcontractor arrangements

The webinar also included an early heads-up on NHSSC’s compliance work around distributor and subcontractor arrangements within tenders. In simple terms, NHSSC should only pay invoices issued by an awarded supplier.

Where a distributor supports the party that has tendered for and secured a place on a framework, NHSSC said that distributor is effectively acting as a subcontractor. According to the example shared in the webinar, this arrangement is compliant provided the distributor has an agreement with the manufacturer that remains valid for the duration of the framework.

NHSSC indicated that this work is still under review and said any companies affected would be contacted individually. For BHTA members, the message is less about an immediate rule change and more about making sure contractual relationships, invoicing arrangements and framework responsibilities are aligned with the awarded supplier model.

Other updates

Other webinar topics included the renaming of the Innovation Team to the Health Innovation Team Members also heard about NHSSC’s inbound logistics service, which provides end-to-end collection and delivery through a nationwide network used by more than 120 suppliers. The webinar also highlighted free support available through The King’s Trust, formerly The Prince’s Trust, which can help companies in high-need areas recruit young people into roles that support the health and social care sector, as part of its wider work to improve opportunities for young people in disadvantaged communities.

A new report from the British Association of Prosthetists and Orthotists (BAPO) has highlighted marked differences in how prosthetic and orthotic services are funded across the UK, raising questions about transparency, consistency, and equity within the current system.

The British Healthcare Trades Association (BHTA), through its Prosthetic and Orthotic Section, supported publication of the report following an external review for clarity and factual presentation. While BHTA did not author the report or direct its conclusions, it has welcomed the findings as a useful contribution to discussion about how prosthetic and orthotic services are commissioned, funded, and tracked across the NHS.

The findings are set out in the report ‘Funding Prosthetic and Orthotic Services Across the UK’.

Prosthetic and orthotic services play an important role in supporting mobility, independence, and quality of life for people with limb loss, neurological conditions, musculoskeletal conditions, and other long-term health needs. Transparent and sustainable funding for these services is important not only for the people who rely on them, but also for the wider health system. Against a backdrop of rising demand and growing pressure on NHS budgets, the report focuses on whether current funding arrangements are sufficiently visible, consistent, and aligned with patient need.

Key findings from the report

The report draws on a UK-wide Freedom of Information exercise carried out in 2025, examining funding data from NHS Trusts and Health Boards over the five financial years from 2020/21 to 2024/25.

Its headline finding is the scale of regional variation in spend. For orthotics, reported spending ranged from £8.87 per head to £0.20 per head, a difference of around 44 to 1. For prosthetics, reported spending ranged from £7.57 per head to £0.49 per head, a difference of around 15.5 to 1. The report says this level of variation raises important questions about how funding is allocated and whether patients in different parts of the UK are experiencing very different levels of provision.

The report also points to significant gaps in financial visibility. More than 60 percent of organisations providing prosthetic or orthotic services were unable to supply complete five-year financial data. Of the 124 Trusts and Health Boards identified as providing relevant services, only 47 were able to provide complete data for one or both services. The report says this makes funding harder to track and accountability harder to assess.

Among the service lines where detailed data was available, the report identifies a difference between funding reported as received and funding reported as allocated directly to services. Across 61 service lines, around £379.9 million was reported as received over five years, while around £333 million was reported as reaching prosthetic and orthotic services. That leaves a gap of £46.93 million, equivalent to 12.35 percent of the total funding in the dataset, which the report says was not allocated directly to frontline prosthetic and orthotic service budgets and was instead retained at organisational level without transparent accounting for its use.

The analysis also examines the effect of inflation on service budgets. While nominal funding rose in some years, the report concludes that these increases often did not keep pace with cost pressures. In 2022/23, funding passed to the 61 service lines increased by 4.87 percent, while average CPI inflation was 10.04 percent, resulting in what the report describes as a real-terms cut of 5.17 percent. Across the period from 2022/23 to 2024/25, it estimates a cumulative loss of purchasing power of around £9.65 million.

Taken together, the findings present a picture of funding arrangements that the report describes as fragmented and difficult to scrutinise. Its central argument is that without clearer reporting and more consistent oversight, it is harder to assess whether prosthetic and orthotic services are being funded fairly and effectively.

Supporting evidence-informed discussion

The report proposes a number of measures aimed at improving transparency and accountability, including mandatory annual reporting of prosthetic and orthotic funding, a national dashboard to improve visibility of funding flows, independent audit of block contract arrangements, and the development of a clearer funding formula linked to population need and outcomes.

For the prosthetics and orthotics sector, the report adds to the evidence base around how funding decisions affect service sustainability and patient access. It also reflects a wider shift towards viewing commissioning through an outcomes-led clinical lens, rather than a purely procurement-led one.

The BHTA has highlighted the value of the report in helping inform constructive dialogue between industry, clinicians, commissioners, policymakers, and patient organisations.

As Ben Taylor, Chair of the BHTA Prosthetic and Orthotic Section, notes in the report:

“BHTA’s Prosthetic & Orthotic Group welcomes this report from BAPO as a timely contribution to improving understanding of how prosthetic and orthotic services are funded and how that funding is allocated and tracked across the system. The report highlights recurring themes that matter to patients and the sector alike: the need for greater visibility and transparency of funding flows, more consistent reporting and accountability, and commissioning decisions that are increasingly viewed through an outcomes-led clinical lens rather than a purely procurement-led one.

“BHTA has not authored this report and does not direct its conclusions; our role has been limited to external review for clarity and factual presentation, and we support its publication to enable constructive, evidence-informed discussion with clinicians, commissioners, policymakers, and stakeholders on the changes needed to secure sustainable, equitable P&O provision.”

Looking ahead

For the BHTA, the report is a useful contribution to ongoing discussion about how prosthetic and orthotic funding is tracked, allocated, and evaluated across the system. The association will continue to work alongside BAPO and wider stakeholders to support constructive engagement on the changes needed to secure sustainable and equitable prosthetic and orthotic provision across the UK.

The Chancellor of the Exchequer, Rachel Reeves, has set out the Spring Forecast 2026 in Parliament, which delivers the UK Government’s spending plans and the economic outlook for the financial year ahead, alongside the Office for Budget Responsibility’s updated ‘Economic and fiscal outlook’.

The BHTA has highlighted some of the key points that may be relevant for member businesses.

The OBR projects that CPI inflation will fall from 3.4 percent in 2025 to 2.3 percent in 2026, reaching the 2 per cent target in late 2026. A lower inflation path may ease some the costs of supplies and running the business over time; however, the outlook emphasises uncertainty and the continued sensitivity of prices and wages to domestic and global conditions.

In addition, the government states that inflation is expected to reduce in 2026–27. If household budgets are less strained, some consumers may have more capacity to spend on health and wellbeing products, home adaptations, and mobility or daily living aids.

The government adds that the OBR expects living standards to rise over the Parliament, with people forecast to be over £1,000 a year better off after inflation.

However, no new measures or plans were announced in the Spring Forecast 2026 for the NHS, social care, or businesses.

David Stockdale, Chief Executive of the BHTA, said: “The Spring Forecast points to inflation returning to target sooner, and to households being better off after inflation, which should help to ease pressure on consumers and support business confidence.

“But the statement is light on new measures, and that is a missed opportunity to address some of the practical barriers facing the healthcare and assistive technology sector.

“Our members support independence at home and in the community, and help services to operate more efficiently, yet there were no new steps on long-standing priorities we have raised, including fair and sustainable funding for community equipment and wheelchair services, greater investment in home adaptations, and the removal of VAT on public access defibrillators.

“We are ready to work with government to ensure that future fiscal decisions support timely access to the products and services people rely on every day.”

Suppliers preparing to submit tenders to NHS Supply Chain should be aware of an important update to sustainability requirements taking effect from 6 April 2026. From this date, suppliers must have achieved Evergreen Level 1 in the NHS Evergreen Sustainable Supplier Assessment by the point of tender close.

The Evergreen Sustainable Supplier Assessment (“Evergreen”) is NHS England’s central platform for suppliers to report sustainability maturity and provide consistent sustainability data to NHS procurement teams. It replaces legacy tools such as the Carbon, Waste and Water Reduction Assessment (CWW) and forms part of the NHS’s broader net zero and sustainable procurement strategy.

What Evergreen Level 1 requires

Evergreen Level 1 represents the baseline sustainability standard that NHS Supply Chain expects suppliers to meet from April 2026.

To achieve Level 1, suppliers must:

• Demonstrate a commitment to achieving net zero emissions by 2050.
• Publish a PPN 006-compliant Carbon Reduction Plan (CRP).
• Report UK Scope 1, Scope 2, and relevant Scope 3 emissions.

A compliant CRP must include emissions data, a clear net zero commitment, board- or director-level approval, annual updates, and publication on the supplier’s website.

Level 1 does not require global emissions reporting or the full social value and modern slavery disclosures that apply at higher Evergreen levels.

How this change supports suppliers

Requiring Level 1 by April 2026 helps suppliers to build foundational carbon reporting practices ahead of 2027 requirements, align their reporting with NHS expectations at an early stage, avoid last‑minute compliance issues as standards tighten, and demonstrate credibility and readiness during tendering.

By setting a clear, achievable minimum standard, this approach supports suppliers to progress in a structured way towards the long‑term net zero commitments across the NHS.

Relationship to the Five Supplier Asks

Evergreen forms part of the NHS’s wider sustainability expectations for suppliers, often referred to as the “Five Supplier Asks”:

1. Carbon Reduction Plan (CRP)
2. Social value reporting
3. Evergreen Sustainable Supplier Assessment
4. Horizon scanning
5. Modern slavery prevention

Suppliers must continue to meet all applicable requirements when bidding for and delivering NHS contracts. Achieving Evergreen Level 1 does not replace obligations under the other sustainability and compliance frameworks.

Practical implications for tendering

• Evergreen Level 1 must be achieved before tender closure from 6 April 2026.
• Submissions should be reviewed and updated annually, or when significant organisational changes occur.
• Further reporting requirements are expected from 2027, including expanded emissions disclosure.

Suppliers intending to bid for NHS contracts should review their current carbon reporting position and ensure that their Carbon Reduction Plan meets PPN 006 requirements well in advance of April 2026.

It is important for suppliers to note that while Evergreen Level 1 will be mandatory from 6 April 2026, it will not form part of the scored evaluation criteria within NHS Supply Chain tenders. Suppliers must meet the required level at the point of tender close in order to be eligible, but their Evergreen maturity level will not attract additional weighting or contribute to qualitative scoring.

Looking beyond April 2026, further requirements are scheduled to take effect in 2027. At that point, suppliers will be expected to publicly report emissions reduction targets and publish a globally scoped Carbon Reduction Plan covering Scope 1–3 emissions.

For further support on Evergreen submissions, suppliers can contact the NHS Supply Chain Sustainability Team at sustainability@supplychain.nhs.uk.

The British Healthcare Trades Association (BHTA) has become aware of a Field Safety Notice issued by Convatec, which is a BHTA member, regarding specific lots of its Esteem Body drainable large pouches.

Convatec has initiated a voluntary Field Safety Corrective Action (product removal) following the identification of a manufacturing variation affecting the drainable tail section of certain pouches. The variation may result in leakage from the tail closure.

Distributors and end-users (healthcare facilities or direct customers) should review this notice carefully. It outlines the affected product codes and lot numbers, explains the nature of the identified issue, details the actions already taken by Convatec, and sets out the specific steps that distributors and end-users are required to follow.

Full details of the manufacturer’s Field Safety Notice can be viewed here.

Products and lots affected

The Field Safety Notice applies to specific UK product codes and lot numbers of Esteem Body drainable large pouches distributed within the timeframe outlined in the manufacturer’s notice.

Distributors and end-users are advised to refer to the official Field Safety Notice for the full list of affected product codes, the specific lot numbers involved, and the relevant distribution period. Only the lots identified in the notice are affected.

Nature of the issue

Convatec has completed an internal health hazard evaluation, which determined that the identified manufacturing variation may result in minor skin irritation in a limited number of users. The potential severity is considered low, according to Convatec, and no adverse events have been reported to date.

Action taken by Convatec

Convatec has confirmed that shipment of affected product has been stopped, and all remaining stock has been quarantined. Corrective and preventive measures are underway to prevent a reoccurrence, a voluntary Field Action across the impacted countries has been initiated, and all relevant regulatory authorities have been notified in accordance with applicable requirements.

Actions required by distributors

Distributors of the affected product should:

• Review inventory immediately to identify any affected product codes and lot numbers
• Quarantine any impacted stock
• Inform any downstream customers who may have received an affected product
• Complete and return the response documentation as outlined in the Field Safety Notice
• Arrange for destruction and credit in accordance with Convatec’s instructions

All required steps and timelines are detailed in the official notice.

Actions required by end-users (healthcare facilities/direct customers)

End-users and healthcare facilities, or direct customers, who may have the affected product should:

• Check product packaging for the listed product codes and lot numbers
• Follow the guidance provided in the Field Safety Notice regarding continued use or disposal
• Complete and return the response form where requested
• Report any issues in line with the manufacturer’s instructions

End-users with questions should contact Convatec Customer Services using the contact details provided in the Field Safety Notice.

Further information

This communication is issued to ensure that BHTA members, distributors, and end-users are aware of the manufacturer’s Field Safety Corrective Action and the steps required.

If you are a distributor or end-user of the affected Esteem Body drainable large pouches, please review the notice carefully, and take the appropriate action without delay.

The UK Government has announced a £4 billion investment to transform support for children and young people with special educational needs and disabilities (SEND). The reforms aim to make every school truly inclusive and ensure children with additional needs receive better, more tailored support.

The government states that these reforms, outlined in the ‘Every child achieving and thriving‘ policy paper, will help end the postcode lottery of SEND support that too many families experience, ensuring more children – regardless of need – can attend their local school.

Key announcements for  BHTA members

Several elements of the government’s plans are particularly relevant to BHTA members supplying assistive technology, mobility equipment, and accessible learning solutions:

• Inclusive Mainstream Fund – £1.6 billion over three years: Funding will be directed to early years settings, schools, and colleges to deliver adaptive teaching and targeted interventions. This includes using technology to support communication, mobility, and sensory needs.
• Capital investment in inclusive spaces – £3.7 billion: The government will create 60,000 new places for children with SEND, including 10,000 already delivered, through major capital investment. This will also fund accessibility upgrades across mainstream schools to create inclusive learning environments.
• Operational transformation funding – £200 million: Local authorities will receive £200 million to modernise how they deliver SEND services in line with national reforms while maintaining current provision.
• Expansion of assistive and adaptive provision: Local authorities will be encouraged to strengthen their SEND strategies with adaptive equipment and inclusive teaching resources, helping students access learning in mainstream settings.
• Local commissioning and partnership working: Funding will be managed through local authorities and Integrated Care Boards, with a focus on collaborative delivery. This may create new opportunities for BHTA members to engage with education and care providers in developing local accessibility and adaptation solutions.

What this means for members

Procurement will increasingly occur through both direct school-level purchasing and local authority-led commissioning, broadening the routes through which members may supply equipment and services.

Settings will also be held accountable for outcomes achieved through inclusion funding, which may increase demand for evidence-based products and supplier-provided training or evaluation support.

The introduction of new digital Individual Support Plans (ISPs) and nationally defined Specialist Provision Packages may, over time, influence how equipment and interventions are specified and evidenced in schools.

Implementation will roll out gradually from 2026, with major capital investment and inclusion funding programmes continuing through to 2030. These measures signal sustained investment in inclusive design and adaptive technology across the education sector. BHTA members providing mobility, access, and assistive products may see greater demand from schools and local authorities upgrading their facilities or implementing early intervention support.

As implementation progresses, members are encouraged to track local procurement plans and explore partnerships with education and health services to support the delivery of these reforms.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a targeted consultation on proposals for the indefinite recognition of CE-marked medical devices in Great Britain (GB). The consultation seeks views on measures intended to protect patient access and ensure the continued supply of safe and effective medical technologies.

For BHTA medical device manufacturer members, this consultation is significant. The outcome will shape the long-term regulatory framework for CE-marked devices in GB, with implications for market access, certification planning and regulatory strategy. This is a key opportunity for members to help inform the final approach.

What is being proposed?

The consultation seeks views on three key proposals:

• Extending current transitional arrangements for devices certified under the EU Medical Device Directive (MDD), aligning GB timelines with the EU’s transition to the EU Medical Device Regulation (EU MDR), to minimise the risk of supply disruption.
• Indefinite recognition of EU MDR and EU IVDR-compliant devices, to reduce the risk of interruption to the supply of medical devices for patients in GB.
• Introducing an international reliance route for a small proportion of CE-marked devices that would fall into a higher risk class under GB rules, to ensure appropriate oversight while maintaining access.

The MHRA has stated that indefinite recognition of CE-marked devices would help ensure continued patient access to essential medical technologies, while being delivered alongside a domestic route to market focused on supporting innovation.

Lawrence Tallon, Chief Executive at the MHRA said: “The number one request that the med tech industry made of us was to provide long term certainty over CE recognition. It is in the best of interests of British patients to ensure continued access to the latest medical devices approved in Europe. It is also in the best interests of the med tech sector to reduce friction and costs of doing business. We have listened carefully and acted on this clear and consistent feedback, which is why we are now pleased to consult on these proposals for indefinite recognition of CE marked medical devices.”

The proposals extend arrangements first introduced in 2023 to recognise CE-marked devices on the GB market and form part of the MHRA’s wider programme of medical device regulatory reform. They also align with wider government policy for other manufactured goods sectors where continued recognition of CE-marked goods has been agreed. Alongside these measures, the MHRA has confirmed that it will continue to strengthen post-market surveillance and improve information sharing with EU partners.

For members supplying CE-marked devices in GB, the consultation represents an important opportunity to provide practical feedback on how the proposed approach would operate in practice and to highlight any potential unintended consequences.

Respond to the MHRA consultation.

The consultation closes on 10 April 2026.

For 2026-2027, the UK Government has confirmed £723 million for the Disabled Facilities Grant (DFG) to enable older and disabled people to live safely, independently, and comfortably at home.

DFGs enable vital home adaptations, including installing equipment like level-access showers, grab rails, stairlifts, ramps, homelifts, and ceiling track hoists, so that people can live in their own homes independently.

For BHTA members installing adaptation equipment, this DFG announcement is welcome, as it means there is more money available in local authorities to facilitate these life-changing installations and improve individuals’ quality of life.

Home adaptations also play a crucial role in supporting the NHS by preventing falls and other accidents in the home, speeding up hospital discharges, and reducing admissions, all of which ease pressure on the health service and help to shift care out of hospital and into the community.

According to the government, the DFG supported around 60,000 people last year.

Minister of State for Care, Stephen Kinnock, said: “We are putting more money into funding life-changing home adaptations so older and disabled people can live safely and independently.”

The 2026 to 2027 DFG allocations are:

• North East: £40,991,139
• North West: £124,356,177
• Yorkshire and the Humber: £69,779,658
• East Midlands: £51,658,126
• West Midlands: £89,602,528
• East of England: £66,019,956
• London: £95,935,564
• South East: £115,148,496
• South West: £69,508,356

The Department of Health and Social Care (DHSC) and NHS England (NHSE) are developing a new MedTech Commercial & Growth Strategy to bring greater cohesion, efficiency, and innovation to the way the NHS buys and uses medical technology.

During a recent industry webinar, representatives from DHSC and NHSE outlined the aims of the strategy and emphasised the need for input from across the MedTech industry – including BHTA members – to help shape its development.

Addressing fragmentation in the medtech landscape

The NHS currently spends around £13 billion annually on medtech across six key categories: medical consumables, implants, equipment, pathology, and medtech digital systems. However, procurement remains fragmented, with duplication of effort, inconsistent standards, and missed opportunities for innovation.

The proposed strategy aims to bring commercial cohesion to this environment by aligning national and local procurement approaches, reducing duplication, and creating efficiencies that benefit both the health service and suppliers. This approach also supports key national frameworks, including the NHS 10-Year Health Plan and the Life Sciences Sector Plan, both of which prioritise innovation and improved patient outcomes.

What the strategy seeks to achieve

The MedTech Commercial & Growth Strategy is designed to:

• Reduce the fragmented buying environment and deliver clear, consistent category approaches that optimise spend and encourage innovation.
• Drive value-based procurement by prioritising outcomes and whole-pathway benefits over lowest-cost decisions.
• Establish a unified commercial framework that makes it easier for suppliers to engage with the NHS.
• Position medtech as a strategic driver for UK growth, supporting national economic priorities.

To deliver these objectives, DHSC and NHSE are developing three core outputs:

1. An overarching commercial strategy – analysing challenges and opportunities across the medtech sector.
2. Sub-category plans – covering major areas of spend with tailored approaches to procurement, innovation, and market engagement.
3. An implementation plan – outlining governance, timelines, and actions to bring the strategy to life.

Collaboration across the system

The programme is being developed collaboratively by DHSC, NHS England, and NHS Supply Chain, with input from industry partners and clinical experts. Dedicated sub-category teams – covering consumables, implants and devices, equipment, and medtech digital – will be supported by commercial and clinical experts from across the system, ensuring the strategy reflects the realities of front-line delivery.

BHTA was recognised in the webinar as a key trade association engaging with the programme, underlining the association’s central role in ensuring that members’ insights inform policy decisions.

How BHTA members can contribute

The DHSC and NHSE are currently in the discovery phase, seeking to understand suppliers’ experiences, challenges, and opportunities through direct feedback. This engagement will help identify practical ways to improve procurement consistency, simplify market access, and accelerate adoption of innovative technologies.

BHTA members are strongly encouraged to share their views by completing the supplier feedback survey before 6 March 2026. Feedback from this survey will directly inform the next phase of the strategy’s development, including detailed category plans and pilot initiatives.

Complete the supplier feedback survey here.  

BHTA encourages all members to contribute their feedback to ensure that the final strategy delivers tangible benefits for both the industry and patients. Members’ insights will help shape a more efficient, transparent, and innovation-friendly medtech environment across the NHS.

In addition, NHSE and DHSC are running the same MedTech Commercial & Growth Strategy industry webinar again on 10 March for suppliers who were unable the recent webinar. Members can register for this webinar here.

A recent House of Lords debate on the English Devolution and Community Empowerment Bill has highlighted long-standing challenges in wheelchair and community equipment provision — and how a proposed amendment could help address them.

The amendment

Amendment 165A to Clause 44 of the Bill, tabled by Lord Hunt of Kings Heath, would add the following to the list of “general health determinants” that authorities must consider when addressing health inequalities:

“(f) the degree of ease or difficulty with which persons have access to high quality wheelchair and community equipment provision.”

This amendment would include wheelchair and community equipment provision in the list of ‘general health determinants’ that authorities need to have regard to as a cause of health inequality.

Debate highlights

Peers from across the House voiced support for the amendment, describing the current state of wheelchair and community equipment provision as fragmented, inconsistent, and underfunded.

Watch the debate from 19:56:28 via this link: https://parliamentlive.tv/event/index/dacc4873-aaf6-4230-83a1-46ad665ad36b?in=19:56:28

Lord Hunt of Kings Heath called the current system “a disgrace,” citing evidence from the Wheelchair Alliance and the All-Party Parliamentary Group for Access to Disability Equipment showing the lack of national standards, independent regulation, and clear repair or complaints processes. “Many disabled people face long waiting times, delays in hospital discharge, loss of independence, social isolation and avoidable deterioration in health and well-being,” he said.

He explained that wheelchair and community equipment services, though often reaching the same individuals, are managed separately — one primarily by the NHS, the other by local authorities and integrated care boards. This division, he argued, leads to inefficiency and poor outcomes. “They should operate in tandem, but they are two distinct systems,” he said, urging closer collaboration.

Lord Shinkwin, speaking as a wheelchair user, said the amendment “puts the issue on the radar,” adding that access to wheelchair and community equipment services “is a health inequality issue.” He warned that the system’s fragmentation and lack of accountability have allowed inequality to become normalised. “Fragmentation may make for better ICB balance sheets in the short term, but history shows that, in the medium term, it is a very costly false economy.”

Baroness Griffin of Princethorpe added that one in three disabled people are still waiting for approved equipment, and that 74 percent of delayed hospital discharges are linked to equipment delays. The amendment, she said, would help make this area of provision a recognised factor in tackling health inequalities.

Government response

Responding for the UK Government, Baroness Taylor of Stevenage acknowledged the concerns but said existing legislation already requires provision of such services. In her response in the House of Lords, she said:

“Local authorities in England already have a statutory duty under various legislation, including the Care Act 2014 and the Children and Families Act 2014, to make arrangements for the provision of disability aids and community equipment to meet the assessed eligible needs of individuals who are resident in their area. In terms of delivery, NHS England supports integrated care boards and wheelchair providers to reduce regional variation in the quality and provision of NHS wheelchairs and to reduce delays in people receiving timely intervention and wheelchair equipment.”

She added that she would raise the issues with colleagues in DHSC and MHCLG and confirmed that the Bill’s existing scope already allows for access to equipment to be considered under “general health determinants.”

Watch Baroness Taylor’s response to Amendment 165A from 16:06:27 via this link: https://parliamentlive.tv/event/index/49b1e807-8829-4a75-a307-4a738052e65b?in=16:06:27

What it could mean for BHTA members

If accepted, Amendment 165A would:

• Formally recognise wheelchair and community equipment provision as a determinant of health.
• Require authorities to show how they are addressing access and quality of provision.
• Potentially influence commissioning priorities and encourage more consistent service standards.

Next steps

The amendment remains under consideration as the Bill progresses through the House of Lords. Its debate marks an important acknowledgment of the essential role that wheelchairs and community equipment play in tackling health inequalities. The BHTA will update members if the amendment is accepted into the Bill.

The NHS Supply Chain Supplier Webinar held in February 2026 provided suppliers with updates on several initiatives shaping procurement and supplier engagement across the health system. Topics included the NHS England Cyber Charter, the Supplier Performance Dashboard, developments in value-based healthcare, and a brief update on the NHS Core List.

Cyber Charter: Strengthening supply chain security

Rachel Million, from the NHS Supply Chain Cyber Team, outlined the latest developments in NHS England’s Cyber Improvement Programme, which is driving higher standards of cyber resilience across the healthcare supply chain. Under the Cyber Charter, suppliers will be contacted by NHS England to discuss their cyber security controls and may be asked to provide evidence of compliance. Further detail is set out in NHS England’s open letter on the Cyber Improvement Programme (the Cyber Charter).

The programme aims to reduce the likelihood and impact of cyber incidents that could affect patient care. Suppliers were advised to review their information security measures, confirm certification status where applicable, and ensure they can provide evidence when requested. NHS Supply Chain noted that cyber resilience is now considered a core component of supply chain assurance.

Supplier Performance Dashboard: Promoting transparency and collaboration

Kate Mokrysz, Supplier Performance and Risk Manager, discussed the Supplier Performance Dashboard, which enables suppliers and NHS Supply Chain to view and compare performance data across cost, quality, service, and sustainability.

Current metrics include service levels, delivery performance, demand management, and data conformance. Further measures are expected to be added over the coming months, including product regulatory compliance, patient safety complaints, sustainability indicators, and information relating to supplier innovation pipelines.

Suppliers who wish to access their own performance data can request dashboard access via their NHS Supply Chain category contact.

Value-based healthcare: Evidence and outcomes

Oliver Booth, Care Pathway Specialist (Midlands), discussed NHS Supply Chain’s ongoing work on value-based healthcare, which focuses on improving outcomes, efficiency, and total cost of care rather than unit price alone.

Suppliers were encouraged to bring forward solutions supported by robust evidence, including real-world data, patient experience, and economic modelling aligned to NHS priorities. Oliver highlighted NHS Supply Chain’s existing value-based healthcare portfolio, which includes case studies demonstrating measurable clinical and system benefits across stages such as pilot implementation, pathway optimisation, financial modelling, and benefits realisation.

NHS Supply Chain is continuing to build the next wave of value-based healthcare opportunities and encouraged suppliers to engage early and share strong evidence packs.

Innovation marketing framework: Consistency and clarity

Fay Allen, Innovation Specialist, outlined a formalised Innovation Marketing Playbook designed to bring greater consistency and clarity to how innovative products are communicated within NHS Supply Chain.

A central element of the framework is the Innovation Brief, a structured document intended to present innovations in a clear, evidence-led format. Each brief includes an executive summary, classification of the innovation, key opportunity highlights, relevant clinical or economic evidence, and practical information such as ordering details and supporting guidance.

By standardising how innovations are presented, NHS Supply Chain aims to make it easier for NHS organisations to identify, assess, and adopt new technologies. For BHTA member suppliers, this approach may provide a clearer route for showcasing evidence-based products that align with value-based healthcare objectives.

NHS Core List

Hamish Makanji, Head of Category – Medical and Surgical Consumables, provided a brief update on the NHS Core List, which aims to simplify procurement for standardised, high-volume consumables through a nationally coordinated route.

From the information presented, the Core List is intended for standardised consumables rather than specialist or bespoke clinical solutions. As many BHTA products, including assistive technology, rehabilitation, mobility, and complex care devices, are tailored to individual patient needs, they are less likely to fall within scope in the near term. While the Core List will continue to expand during 2026, its relevance to most BHTA members is expected to remain limited.

BHTA will continue to monitor NHS Supply Chain developments and share relevant updates to support members in understanding changes across the procurement landscape.

The NHS Supply Chain has announced a one‑hour pre‑market engagement (PME) webinar introducing the forthcoming Aids for Daily Living (ADL) 2027 framework, scheduled for 2pm on 10 February 2026. This session offers BHTA members an opportunity to understand the scope, timelines, and participation process for this major upcoming framework.

The ADL 2027 framework aims to support independence at home and facilitate timely hospital discharge through a comprehensive range of products. Categories will include bathing aids, toileting aids, bedroom and home equipment, mobility aids, and paediatric devices, as well as a managed service for Community Equipment Loan Services.

The framework also places a strong emphasis on reuse, refurbishment, and sustainability, aligned with NHS Supply Chain’s circular economy and design for life principles — part of a wider shift toward sustainable procurement and product lifecycle thinking that the NHS and medtech sector are pursuing together (read more about the Design for Life initiative here).

What the webinar will cover

The webinar will provide an overview of the framework’s commercial aims, specifications and product categories, the procurement process, and key milestones. It will also outline how members can engage during the PME period, which remains open until 6 March 2026. This session forms part of NHS Supply Chain’s wider engagement programme.

Who should attend

BHTA members involved in the supply of aids for daily living, mobility aids, community equipment, or related products and services are encouraged to attend. The session is particularly relevant for organisations working in assistive technology, rehabilitation, independent living, or healthcare product distribution, including small and medium‑sized enterprises (SMEs) and voluntary, community and social enterprises (VCSEs).

How to register

To attend, members should register their Expression of Interest (EOI) via either the Jaggaer portal or the Find a Tender notice.

Once registered, attendees can sign up for the webinar through the official Microsoft Teams event link.

For any questions ahead of the session, please contact the NHS Supply Chain Aids for Daily Living team at aidsfordailyliving@supplychain.nhs.uk.

BHTA members are encouraged to participate in this engagement opportunity. The association will continue to monitor updates on the framework and share relevant information as procurement progresses.

Get to know Chris Goodban – Verlingue Client Director and your new point of contact for the BHTA Members’ Scheme

Verlingue is proud to be the preferred insurance provider for BHTA members, and with that comes a commitment to personal, specialist support. To help put a face to the name, we caught up with Chris Goodban, Client Director at Verlingue and the new lead for the BHTA Members’ Scheme.

Chris, tell us a bit about your role at Verlingue.
I joined Verlingue about 18 months ago, and around seven months ago I took on responsibility for the BHTA Members’ Scheme. As Client Director, I’m the main point of contact for BHTA members, whether that’s reviewing existing cover, helping with renewals, or simply answering questions when something isn’t quite clear.

What does that mean in practice for BHTA members?
My job is really about making insurance feel straightforward and relevant. Every business is different, so I spend time getting to know members properly, understanding their risks and challenges, and then offering advice that’s practical and tailored. Insurance should support your business, not complicate it.

You’ve been in insurance a long time – what experience do you bring to the role?
I’ve been a broker for around 30 years, working across commercial insurance, so I’ve seen a lot of different scenarios. That experience helps me cut through complexity and focus on what genuinely matters for each client. Just as important, though, is building strong relationships and being approachable — I want members to feel comfortable picking up the phone.

What do you enjoy most about working with BHTA members?
The variety. No two businesses are the same, and I enjoy learning how different organisations operate. It’s very rewarding when you can offer advice that genuinely makes a difference or gives someone peace of mind.

And outside of work – what keeps you busy?
Family is a big part of my life. I’m married to Stephanie, and I’m a proud parent and grandparent. I’m also usually outdoors when I can be – cycling, mountain biking, or walking our Lakeland Terrier through the countryside. I’m a bit of a technology enthusiast too, so I enjoy keeping up with the latest gadgets and innovations.

Finally, how can BHTA members get in touch?
I’d encourage any member to connect with me, whether you’re due a review or just want a conversation about your current cover. The Members’ Scheme is there to support your business, and I’m always happy to help explore how it can work for you.

BHTA members are invited to contact Chris to review their insurance or discuss how the Members’ Scheme can support their business.

Chris Goodban, Cert CII – Client Director
M: +44 (0) 7841 775699
Email: chris.goodban@verlingue.com
W: www.verlingue.com

The British Healthcare Trades Association (BHTA) has welcomed Younique Healthcare as a new member, a retailer that specialises in assessment-led mobility and access solutions, from specification to installation and aftercare.

The BHTA spoke to directors Andy Haines and Lee Cadman to learn more about Younique Healthcare’s assessment-led approach, service pathway, plans for growth, and why it joined the association.

---

About Younique Healthcare’s co-founders

Co-founded by Andy Haines and Lee Cadman, Younique Healthcare is led by two directors with complementary strengths and a shared emphasis on tailored solutions where comfort, posture, and real-world usability matter.

Andy, Director for Commercial and Product Development, is a healthcare mobility specialist recognised for pairing commercial leadership with practical clinical problem-solving. His work spans independent assessments, complex seating set-ups, and collaboration with charities and partner organisations to match people with the right equipment and support, as well as a wider business development and product focus within the UK medical devices and mobility space.

Lee, Director for Retail and Services, brings a customer-first, operations-led approach, with a hands-on focus on personalised assessments, high-quality equipment, and consistent follow-through, helping to turn complex needs into workable, dignified day-to-day outcomes. Beyond Younique Healthcare, Lee is involved in community-facing mental health and disability work through The Black Country Blokes C.I.C., which won the King’s Award in 2025.

What is Younique Healthcare? 

Established in 2018, Younique Healthcare supports disabled people, families, clinicians, and care settings with assessment-led supply, installation, and aftercare, aiming for safe, practical outcomes that improve independence, comfort, and day-to-day function.

Its services cover wheelchairs and specialist seating, moving and handling equipment, access solutions (including modular ramps and threshold options), and LOLER inspections and certification.

Younique Healthcare operates an assessment-led pathway, which involves understanding needs and risks, such as the environment, user ability, carers, transfers, skin integrity, and safety; confirming measurements and constraints; proposing suitable options; supplying, installing, and commissioning solutions; and then handover, user guidance, and aftercare/support.

Andy describes the company’s ethos as “inclusive by design”, balancing independence, safety, and value, while avoiding “one-size-fits-all” provision. Lee adds that this is underpinned by clear assessment and record-keeping, installation standards, and aftercare.

Younique Healthcare, which is Disability Confident-registered, works with individuals, families, occupational therapists, physiotherapists, case managers, care homes, supported living providers, care agencies, and local authority/public sector-style referrals, where applicable.

“We are a disabled family operating within the market that we serve and that serves us,” Andy added.

Some of Younique Healthcare’s supply partners include BHTA members like Permobil, Sunrise Medical, Etac, and BES Healthcare.

Future plans

Looking ahead, Younique Healthcare says it is navigating economic pressures and ongoing supply chain constraints, while exploring opportunities to develop its own product ranges. The team is also planning either a new shop or a consolidation into a larger Midlands premises.

Younique Healthcare is also planning to open another shop or consolidate into one bigger premises in the Midlands.

The decision to join the BHTA

The directors say joining the BHTA builds on their existing awareness of the association and supports a wider programme of training and development. “We felt the time was right to nail our colours to the mast”, Lee commented.

---

To find out more about how the BHTA can support your business and how to become a BHTA member, visit this page.

The British Healthcare Trades Association (BHTA) is sharing important safety information on behalf of SunTech UK, trading as eFOLDi. SunTech UK is a member of the BHTA, and the association is aware of this Field Safety Notice (FSN).

On 21 January 2026, SunTech UK issued a Field Safety Notice concerning the eFOLDi powerchair, following the discovery that several safety warnings were missing from earlier versions of the product’s Instructions for Use (IFU).

This action has been taken as a precautionary measure. There have been no reported incidents, injuries, or adverse events related to this issue. The update reflects SunTech UK’s continued commitment to ensuring that all users have complete and accurate safety information.

About the field safety notice

As part of a routine internal review, SunTech UK identified that certain safety warnings were omitted from previous versions of the eFOLDi powerchair’s instructions. The updated IFU now includes these additional safety statements and clarifies that the product is designed for indoor and limited outdoor use on smooth, level surfaces, such as homes, assisted living facilities, shopping centres, offices, and hospitals.

Although users should have been informed of these safety considerations during product demonstrations and handovers, SunTech UK has issued this written update to ensure all users and retailers have clear, complete information.

The Medicines and Healthcare products Regulatory Agency (MHRA) has been notified of this corrective action.

Key safety warnings

The following safety warnings must be reviewed and followed by all eFOLDi powerchair users and retailers:

• Do not get on or off the eFOLDi powerchair with the handbrakes disengaged
• Never operate the powerchair without the anti-tip wheels securely in place
• Always apply manual brakes before getting in to or out of the power chair
• Not intended to be used as a seat in a motor vehicle
• The Attendant Control has no impact on the braking system of the powerchair
• Do not use the powerchair on a ramp/slope if the battery is out of power without applying manual brakes, it does not have any electric brake without power
• Use of this electric wheelchair adjacent to or stacked with other electrical equipment should be avoided because it could result in improper operation
• Portable RF communications equipment (including peripherals such as antenna cables and external antennas) should be used no closer than 30cm (12 inches) to any part of the electric wheelchair
• If the use location is near (e.g. less than 1.5km from) AM, FM or TV broadcast antennas, before using this equipment, it should be observed to verify that it is operating normally.

These warnings are essential to prevent unintended movement, falls, instability, and interference that could affect safe use. The revised IFU also includes further details on how to identify damage to the battery or charger, information relating to electromagnetic compatibility, updated performance specifications, and clearer instructions for transportation, maintenance, and refurbishment.

Risk awareness

The absence of these warnings in earlier documentation could lead to unintended use that increases the risk of:

• Loss of stability when getting in or out of the device
• Tip-over events if anti-tip wheels are not installed
• Unexpected movement when handbrakes are not engaged
• Unsafe use as a seat in a moving vehicle
• Abnormal behaviour due to electromagnetic interference

Although no such incidents have been reported, SunTech UK has taken this precautionary action to minimise any potential risks and ensure continued user safety.

Actions required

To ensure the continued safe use of the eFOLDi powerchair, SunTech UK requests that users and retailers take the following steps without delay.

For users

1. Download and read the official Field Safety Notice.
2. Review and follow all safety warnings listed above.
3. Confirm that the anti-tip wheels are securely installed before use.
4. Always apply manual brakes when getting into or out of the powerchair.
5. Never use the powerchair as a seat in a vehicle.
6. Dispose of any earlier versions of the Instructions for Use while keeping the information relating to your device purchase and serial number.
7. Familiarise yourself with the new instructions for use and retain them for future reference.
8. Respond to the Field Safety Notice by scanning the QR code or completing the form provided in the notice to confirm acknowledgement.

For retailers

1. Download and review the official Field Safety Notice.
2. Contact all customers who have purchased the affected eFOLDi powerchair and provide them with a copy of the updated IFU and Field Safety Notice.
3. Confirm receipt of the notice by scanning the QR code or completing the retailer response form in the notice.
4. Maintain a record of all communications sent to customers as part of this corrective action.

For further information or support, contact:

SunTech UK
25 Ormside Way, Holmethorpe Industrial Estate, Redhill, Surrey, RH1 2LW
📞 +44 (0) 20 3143 5168
📧 services@efoldi.com
🌐 www.efoldi.com

Buying from a British Healthcare Trades Association (BHTA) ensures that the company you’re buying from adheres to the BHTA’s strict Code of Practice, which is approved by the Chartered Trading Standards Institute (CTSI).

This means BHTA members commit to providing a level of service above and beyond that of their legal obligations, so you can expect to receive expert advice, excellent customer service, and never be pressure sold any products or services.

There are several ways to identify whether a company is a BHTA member:

• Look for the BHTA logo on their shop window, company vehicle, or website.
• Ask to see their BHTA Membership Certificate.
• Check our member directory. This contains an up-to-date list of all our members.

Warning: A company could fraudulently display the BHTA logo on their website, even if they are not a member. To ensure that a company is a member, the BHTA logo on the company’s website should be clickable and take you through to the CTSI member verification page to confirm that the company is a member.

The CTSI member verification page looks like the below:

If you are still unsure whether a company is a BHTA member, please contact us to verify their details by calling 020 7702 2141 or emailing info@bhta.com.

The British Healthcare Trades Association (BHTA) is calling on its members to respond to a new UK Government consultation that is seeking views from industry to modernise laws on powered mobility devices, which includes electric wheelchairs and mobility scooters.

Launched on 6 January 2026, the Department for Transport’s (DfT) 12-week consultation seeks to review size, speed, and usage rules to better reflect modern technology and improve safety.

According to the DfT, current legislation is nearly 40 years old and does not reflect the technological advances that have transformed powered mobility devices. For example, some modern wheelchairs used by adults and children exceed the current maximum legal weight limit, meaning they can only legally be used on private land.

The consultation seeks views on how regulations should evolve to better support people who rely on powered mobility devices, while ensuring safety for everyone who uses roads and pavements.

A variety of crucial topics are covered in the consultation, including:

• Updating terminology in law, replacing outdated terms such as “invalid carriages” with language that reflects modern attitudes and respect for users
• Clarifying where powered mobility devices can be used – on roads, pavements, or other spaces
• Reviewing size, speed, and age requirements for larger devices
• Considering whether two-person tandem devices should be permitted on UK pavements and roads
• Exploring whether other devices, such as powered transporters, should be allowed on public roads or pavements when used by disabled people or those with reduced mobility

Simon Lightwood MP, Minister for Roads and Buses, said: “Powered mobility devices give people independence and freedom and the law should enable their safe use. This consultation is a chance for users and organisations to help us modernise these outdated rules and ensure they meet today’s needs.”

This consultation focuses only on the legislation that governs the use of mobility devices, or powered mobility devices, on the road and pavement in Great Britain.

The consultation deadline is 11.59pm on 31 March 2026. BHTA members can respond online here.

DfT says that a summary of responses, including the next steps, will be published within three months of the consultation closing. 

The UK Government has announced an additional £50 million cash injection for the Disabled Facilities Grant (DFG) for 2025-26, which will enable thousands more older and disabled people to live independently in their own homes.

This extra investment will be allocated to local authorities in February 2026 and brings total DFG funding for 2025-26 to £761 million.

For BHTA members installing essential adaptation equipment, this extra DFG cash injection will come as a welcome announcement, as it means there is more money available in local communities to facilitate these life-changing installations and improve individuals’ quality of life.

DFGs enable vital home adaptations such as stairlifts, ramps, accessible bathrooms and kitchens, and assistive technologies. This includes mobility and daily living aid equipment like grab rails, ceiling track hoists, homelifts, and wetrooms. It means that people can live at home safely, independently, and comfortably.

Minister of State for Care, Stephen Kinnock, said:“Everyone deserves to feel safe and independent in their own home. A stairlift or an accessible bathroom might seem like a small change, but for thousands of older and disabled people these adaptations can be life changing. They help people move around freely, stay close to family and friends, and live with dignity.

“This £50 million boost could support around 5,000 more people to make these vital changes to their homes so they can remain independent and comfortable rather than face a hospital stay or a move into residential care.

“Home adaptations also play a crucial role in easing pressure on our NHS – preventing falls, speeding up hospital discharges and reducing admissions. This investment is part of our commitment to shift more care out of hospital and into the community, where people want to be.”

The DFG supports around 60,000 older people and people with disabilities each year, with an average grant of around £10,000.

Home adaptations also play a crucial role in supporting the NHS by preventing falls and other accidents in the home, speeding up hospital discharges and reducing admissions – easing pressure on the health service and helping to shift care out of hospital and into the community.

A number of British Healthcare Trades Association (BHTA) members are giving positive feedback on a Level 3 Trusted Assessor qualification for retailers that raises standards in the independent living sector.

Background on the Trusted Assessor course

In 2024, the BHTA worked in partnership with Trusted Assessing and Care Training (TACT) to launch a new course designed for retailers of independent living equipment. Delivered by TACT, the ‘Trusted Assessors: Assessing in the Retail Environment’ course is designed to accredit retailers as Trusted Assessors.

The course enables customer-facing staff to learn the skills involved in assessing for suitable home adaptations equipment. This development has enabled organisations across the sector to upskill staff to a standardised, independent set of competencies long recognised within health and social care.

The Trusted Assessor Model

Trusted Assessor competencies, first defined in 2005, are now widely used across the UK by health, social care, housing, and care teams. The qualification teaches learners to adopt an occupational therapy–based approach to assessments, combining theory with hands-on practical skills. Crucially, trainees learn how to identify when a case is complex and requires referral to an occupational therapist (OT). Trusted Assessors are qualified to assess a person’s needs and identify the most suitable equipment and adaptations to support independent living.

TACT’s OTs deliver the teaching, support learners with their assignments, run free monthly top-up webinars, and make additional resources available for free on its website. Learners complete training modules and a homework assignment to demonstrate their understanding and practical application of the course content.

As more organisations adopt the Trusted Assessor model, the independent living sector is better positioned to meet growing demand, reduce pressure on overstretched OTs, and ensure people receive timely, accurate guidance on the equipment that supports independent living.

Strengthening ties with local pathways

Many retailers have found that the qualification not only enhances internal skill levels but also improves collaboration with local equipment and assessment pathways.

TPG DisableAids, a BHTA member based in Hereford, offers a strong example. Director Alastair Gibbs explained: “For TPG DisableAids the Trusted Assessor scheme has been a real boost. We have various staff trained from level 2 to level 4, and it has given us real credibility with housing associations and local authorities. Those looking for a differentiator and an indicator of commitment to quality found it in our association with BHTA and Trusted Assessor.”

This credibility strengthens tender opportunities for providers supplying independent living equipment, as the qualification offers a clear benchmark of assessment quality.

Recognition is growing within the OT profession as well. Brett Gilham from BHTA member company Laybrook noted: “We know how busy many OTs are, so the fact that we can demonstrate we have been trained and can provide assistance in the assessment process benefits all parties. It also means our staff across all levels have been trained to a set standard for assessing.”

Reassuring the public

Retailers are also seeing value in highlighting the qualification to the public. Dolphin South West, a BHTA member based in Devon, newly qualified, has launched a communications campaign to promote its enhanced capabilities.

Antonia Nixon, from Dolphin South West, said: “The Dolphin team enjoyed the training—learning and reinforcing what they know—and now we’re keen to let people know what this means when they deal with us.”

Acting as a regional hub

Some providers are taking the Trusted Assessor approach even further.

On 10 and 11 December 2025, BHTA member Wenman Healthcare hosted two free training workshops for organisations across the region that provide advice to the public on independent living. Twenty-four learners attended the two, one-day Level 2 accredited courses, delivered by TACT.

Attendees importantly represented a broad spectrum of local services, including NHS social prescribers, district housing teams, regional disability and carer charities, and homecare providers, who also benefited from the opportunity to network with peers.

TACT estimates that the programme will help more than 100 residents every day who receive advice from these organisations all year round, demonstrating the potential significant regional impact this training would have if rolled out more widely.

Participants reported a clear increase in their confidence when supporting older and disabled people. The course covered common health conditions, how local health and social care systems operate, communication skills, and key risk factors. Learners also explored a wide range of independent living equipment and typical solutions used across the region.

Confidence in the topic of independent living equipment rose from 52 percent being fairly or very confident pre-course to 100 percent afterwards. Both Wenman Healthcare and TACT were delighted with the outcomes.

Clare Barber, Director and OT at TACT, enthused: “We are passionate about improving access to much-needed equipment, and upskilling people working locally is one of the best ways to ensure residents get timely, accurate advice. Navigating the regional landscape of aids, equipment, and adaptations can be challenging, and understanding what’s available and how to access it can speed things up immeasurably.”

Ian Wenman, Managing Director at Wenman Healthcare, added: “People often aren’t aware of their entitlement to a needs-based assessment for equipment and home adaptations. This can ensure essential equipment is delivered to their home. They often struggle to know what equipment is relevant and helpful to a particular health condition. 

“Families frequently want to explore additional items, and they can try a wide range—without obligation—by visiting our showroom. Our Trusted Assessors identify what’s needed and provide impartial advice, as well as providing a free home visit when required.”

The initiative demonstrates how retailers can act as local hubs for information, training, and support. By engaging organisations across their community, Wenman Healthcare aims to speed up access to essential equipment and strengthen cross-sector relationships.

Course training options

BHTA members can choose from either a one-day in-person course run at their premises or opt for the live webinar version delivered over a series of three dates.

In 2026, the webinar version involves studying for three three-hour live webinars running on:

• 13 March
• 20 March
• 27 March
• 4 November
• 11 November
• 18 November

Alternatively, members opt to join one of the main Trusted Assessor courses that include practical workshops, and these can be directly commissioned or accessed through TACT’s open courses running regionally.

All versions of accredited courses require learners to complete and pass a homework assignment, and, once qualified, Trusted Assessors can join the monthly webinar top-ups for 12 months.

Find out more about the ‘Trusted Assessors: Assessing in the Retail Environment’ course and booking options here.

The British Healthcare Trades Association (BHTA) has welcomed Gibb Group as a new member.

Gibb Group provides medical service provision across multiple industries, operating in the UK and globally. The BHTA recently caught up with Karen Scott, Head of Clinical Services & Innovation at Gibb Group, to learn more about the organisation, its services, and the value of BHTA membership.

---

A commitment to safe, reliable, and innovative products and services

Gibb Group Medical & Rescue is part of a wider group called Gibb Group Limited, which is made up of four key divisions:

• Medical & Rescue: Expert medical and rescue training, equipment, governance, compliance, and staffing solutions.
• Safety & Survival: high-quality PPE, safety products, and workwear.
• Tools & Supplies: Tools and control solutions, along with maintenance, repair, and operations supplier.
• Rental & Service: Short-term and long-term rental options and PPE and survival equipment inspection, testing, cleaning, and laundering services.

Gibb Group Medical & Rescue stives to keep people safe and operations running by delivering first-class turnkey solutions, with high-quality products and services.

Karen said: “Our ethos is built on safety, reliability, and innovation. We partner with leading organisations across energy, marine, and industrial sectors to deliver solutions that protect lives and enable operational success.”

Gibb Group works with airport and local authority fire and rescue services, and, since 2016, it has become one of the leaders in medical service provision for the renewable energy industry.

“Our market-leading EURIECA® programme of training, medical equipment, and clinical governance has been widely adopted in both onshore and offshore wind at home but also abroad in the US and Europe,” explained Karen. “We have ambitious plans to deliver the same services in the APAC region, where there is a growing wind energy market.”

Beyond its impact in the renewable energy industry, Gibb Group has also experienced major growth in its provision of offshore medics supporting wind farm organisations, where it deploys an experienced healthcare professional, complete with the equipment they require to do their role, to the point of injury.

Karen continued: “So we are the end users of a lot of the products we provide, as well!”

Bringing two decades of experience to a global market

Founded in 2005 as Trauma & Resuscitation Services (Trauma Resus), the organisation began as a specialist provider of trauma training and clinical governance to the UK’s fire and rescue services.

In 2024, Trauma Resus was acquired by Gibb Group and now operates as its Medical & Rescue division. This acquisition enabled access to a broader global network, expanded training capability, and equipment supply across oil, gas, marine and renewable sectors.

Although the name has changed, the heart of the organisation remains the same, with the same people, principles and dedication to excellence.

Karen added: “Over two decades, we’ve built strong relationships with our customers, suppliers, and partners — and have been privileged to work alongside some of the most skilled and passionate professionals in the industry.”

Tangible benefits of being a member of the BHTA

One of the main reasons Gibb Group joined the BHTA was to access expert guidance on regulatory changes and product recalls, which can create uncertainty.

Membership also closely aligns with Gibb Group’s commitment to quality and professionalism.

Karen said: “It gives us a stronger voice in shaping industry standards and offers invaluable networking and knowledge-sharing opportunities.

“Being part of a larger association can strengthen our voice, but we are also hoping to bring our expertise and knowledge to the association as well and make a positive impact.”

Gibb Group prides itself on maintaining rigorous standards, reflected in its ISO accreditations and memberships of professional bodies.

Karen continued: “Additionally, our memberships in professional associations not only demonstrate our dedication to staying abreast of industry trends and best practices but also provide us with valuable networking opportunities and access to resources that further enhance our capabilities.

“These accreditations and memberships serve as a testament to our unwavering dedication to delivering the best services and products whilst upholding the highest standards of integrity and reliability, so BHTA was a natural alignment with our goals.”

International expansion on the horizon

Looking ahead, Gibb Group aims to continue expanding its Medical & Rescue offering in the UK and internationally. The company already operates across the UK, EU, USA, and APAC regions and is focused on growing its global customer base.

To support these ambitions, Gibb Group has recruited staff into international development roles.

Karen enthused: “We are excited to see where we are 12 months from now!”

---

To find out more about how the BHTA can support your business and how to become a BHTA member, visit this page.

The British Healthcare Trades Association (BHTA) is aware of a voluntary Field Safety Notice issued by BHTA member company Permobil concerning a limited number of M- and F- Corpus series power wheelchairs. This article explains what the notice means, who may be affected, and what steps users and providers should take.

What has been identified?

Permobil has confirmed that an incorrect bushing was used during assembly on some M- and F- Corpus series power wheelchairs manufactured between 10 July 2025 and 25 July 2025. Further technical detail is set out in the official Field Safety Notice published by the MHRA, which can be viewed here.

A bushing is a small protective sleeve designed to reduce friction and vibration between moving parts. In the affected chairs, the incorrect bushing may reduce structural integrity during a hard front-end impact.

The component most affected is the integrated neck injury protection mechanism, which is designed to help reduce the risk of neck injury in the event of a collision.

What is the level of risk?

According to Permobil’s risk assessment, the likelihood of failure is low. However, because an increased risk has been identified under specific conditions, Permobil is carrying out a re-work on all affected units as a precaution.

There have been no instructions to stop using the chair in everyday situations. The notice focuses on ensuring that the device continues to meet its intended safety performance.

Which devices are affected?

Only a limited number of Permobil M- and F- Corpus series power wheelchairs are affected. The official Field Safety Notice includes full technical details and the complete list of affected serial numbers. These are specific units identified by serial number and manufacturing date.

If a chair is affected, the owner or service provider will be contacted directly. If you are unsure whether a device is included, your local provider can confirm this for you.

What happens next?

Permobil has instructed local providers to arrange a re-work of affected chairs. This corrective action will replace the incorrect component and restore full compliance with safety requirements. Providers will contact users directly to arrange the work at a suitable time.

Advice while waiting for re-work

While waiting for the corrective work to be completed, Permobil recommends avoiding car transportation of the chair, where possible, to minimise any risk associated with high-impact situations This is a precautionary measure and does not affect normal day-to-day use.

Contact information

Permobil advises that if you have any questions relating to this Field Safety Notice, you should contact your local provider or Permobil Customer Support.

Permobil Customer Support:

• Telephone: +46 60 787 90 60
• Email: customer_support_se@permobil.com

Permobil also requests that any device-related incidents are reported directly to the manufacturer at incident.report@permobil.com.

The British Healthcare Trades Association (BHTA) would like to inform members, healthcare professionals, and users that Etac, a BHTA member, has issued a Field Safety Notice (CCR-2508-11) concerning specific models of its Molift Mover and sling bar products.

Overview

Etac has identified a potential issue affecting certain Molift Mover 205 and Molift Mover 300 mobile patient lifters, as well as Molift 2-point and 4-point sling bars. The issue was discovered following a customer report during assembly and load testing of a Molift Mover 300, the bolt for mounting the lifting bar broke. Upon further investigation, Etac discovered that the defect occurs as a result of deformation of the materials involved between the lifting bar and the arm of the Molift Mover. Such deformation can lead to limited mobility in the joint, which prevents proper functionality of the equipment.

Corrective action

Etac has initiated a proactive corrective action to address this issue. The manufacturer confirms that:

• Replacement units are being provided for all potentially affected products.
• Continued use of existing units is safe, provided that the lifting bar moves freely and remains vertical throughout the lifting cycle, with or without load.
• If the lifting bar does not move freely, or if there is any doubt about its function, the unit should be taken out of service immediately.
• Replacement of affected components will take place in stages and is expected to be completed by the end of 2026.

This action applies to specific batches of Molift Mover 205 and 300 units, and corresponding sling bars shipped between February and August 2025. Details of affected serial numbers are included in Etac’s official Field Safety Notice.

Member and user guidance

BHTA members and healthcare providers that have supplied or use these products should:

1. Review the Field Safety Notice in full.
2. Inspect affected units immediately for proper functionality.
3. Contact Etac or its authorised distributor for support, replacement scheduling, or further clarification.
4. Share this information with relevant colleagues, care facilities, and users.

Further information

The notice has been filed with the MHRA. BHTA members can read the full Field Safety Notice here.

The collapse of NRS Healthcare in August 2025 sent shockwaves through the healthcare sector, disrupting essential provision for thousands of people who rely on vital aids to live safely and independently.  

Given the scale of the impact, the UK Government has now issued a response to a key parliamentary question examining both the collapse of NRS Healthcare and its impact on vital healthcare equipment services. 

However, while the response acknowledges the importance of community equipment and outlines short-term actions taken during the liquidation, it offers no long-term assurances to prevent a similar collapse from happening again.

A key reason there was not a system-wide failure was due to the hard work by BHTA members and others to step in and take on contracts and ensure continuity of services. This has so far gone unacknowledged by government.

Below is the full written question and government response for BHTA members’ reference: 

NRS Healthcare: Insolvency 
Asked by Lord Allan on 17 November 2025 
“To ask His Majesty’s Government what assessment they have made of the impact of the insolvency of NRS Healthcare on the provision of community equipment services.” 

Answer from Baroness Merron, Parliamentary Under-Secretary of State for Health and Social Care (4 December 2025) 

“Community equipment, such as wheelchairs, hoists, and other specialist medical equipment, forms an important part of many people’s health and care support package. Such equipment can be critical in supporting better care outcomes, can enable people to remain in or return to their homes as the primary setting for care, and can avoid unnecessary stays in hospital or care homes. 

“Local authorities have statutory duties under the Care Act 2014 and the Children and Families Act 2014 to arrange for the provision of disability aids and community equipment to meet the assessed needs of individuals in their area. While some local authorities provide these services themselves, many have contracts with external suppliers, such as NRS Healthcare. The Department does not have a statutory role in the provision of community equipment. 

“However, as part of NRS Healthcare’s liquidation process, the Government made available short-term funding to the Official Receiver to cover the essential operating costs of NRS Healthcare and its affiliated companies. This funding ensured that trading was able to continue for a limited time, minimising disruption by providing crucial time for local authorities to put alternative supply in place. The Department continues to monitor the situation in affected local authorities through Partners in Care and Health, a Department funded programme run in partnership with the Local Government Association and the Association of Directors of Adult Social Services.” 

BHTA’s call for urgent, coordinated action 

To protect service users and support the businesses that deliver this essential work, the All-Party Parliamentary Group (APPG) for Access to Disability Equipment’s recent report points to a series of important recommendations to the UK Government to improve community equipment services as a whole:

• Develop a National Strategy for Community Equipment – led by a dedicated Minister, ensuring national consistency, accountability, and funding reform.
• Reform funding and commissioning to focus on quality, not just cost, and support sustainable innovation.
• Reduce waiting times and delays through workforce investment and better coordination between the NHS and local authorities.
• Improve communication and transparency with families and carers through a national framework and central data monitoring.
• Create a National Advisory Board to give equipment users and carers a real voice in service design and delivery.
• Strengthen reuse and recycling systems so equipment no longer sits unused while others go without.

BHTA stands ready to work with the government, local authorities, the NHS and industry partners to help shape a more resilient and sustainable future for these essential sectors. The people who rely on this equipment — and the professionals who deliver it — deserve a system that is robust, responsive, and protected from preventable disruption. 

Introduction

The House of Lords recently held a debate examining the UK Government’s plans to publish a strategy for wheelchair provision through NHS and social care services. The question was raised by Lord Hunt of Kings Heath, who opened the discussion by highlighting long-standing systemic issues within wheelchair and community equipment provision.

Responding on behalf of the government, Baroness Merron acknowledged the concerns raised across the debate. She confirmed, however, that the government has no plans to publish a national strategy for wheelchair provision, a point that drew disappointment from many peers.

The debate explored wide-ranging issues including service fragmentation, delays in assessments and repairs, unsuitable equipment, lack of national oversight, supply chain vulnerabilities, and the human impact on independence and dignity.

Watch the debate here. Begins at 12:53:10.

Fragmentation, inconsistency, and the postcode lottery

Peers highlighted significant inconsistencies in wheelchair and community equipment provision across England. Lord Hunt observed that services are “inconsistent and under-resourced,” noting that each local authority and integrated care board (ICB) operates differently, resulting in a postcode lottery.

Lord Kamall outlined stark disparities in eligibility criteria between regions. For example:

• North Bristol defines regular use as four times weekly.
• Oxford defines it as at least three days per week.
• Wirral and West Cheshire define it as “more often than not.”
• West Suffolk requires a driving assessment, home accessibility checks, and GP clearance.
• North West London uses a tiered categorisation system.

Lord Kamall said: “A delay in receiving a wheelchair is not simply an inconvenience or statistic, it is a barrier to living a fuller life.”

These differences affect who qualifies for a wheelchair, the type of equipment provided, and the level of support available. NHS England’s dataset shows significant regional variation in meeting the 18-week waiting-time standard. Data provided by the British Healthcare Trades Association (BHTA) was also cited in the debate, showing that only around 80 percent  of users receive a wheelchair or modification within 18 weeks—below the national 92 percent  target—with even longer waits for people with complex needs. in meeting the 18‑week waiting-time standard.

Peers also drew on detailed evidence from national reports. The Wheelchair Alliance report highlighted inconsistent provision, long delays in assessment, unsafe temporary equipment use, and a lack of clear repair pathways. It showed how inadequate provision undermines independence, contributes to deterioration in physical and mental health, and delays discharge.

The APPG for Disability Equipment report about community equipment services described the system as inconsistent, underinvested, fragmented and lacking leadership. It identified staff shortages, supply chain weaknesses, recycling delays, dependency on single contracted providers, and widespread dissatisfaction among users and carers with current provision.

Delays, bureaucracy, and real‑world consequences

Peers shared examples illustrating the impact of delays and bureaucratic barriers. Lord Harries recounted the case of Rhys Porter, a young man with cerebral palsy who went two years without essential equipment, leaving his family to manage unsafe manual handling that put them all at risk.

Peers described consequences including loss of independence, avoidable deterioration in health, delayed hospital discharge, social isolation, and increased pressure on carers.

The Wheelchair Alliance report further documented how inadequate equipment provision leads to preventable complications and unnecessary healthcare use.

Employment and economic impact

Several peers, including Baroness Lane‑Fox, highlighted how wheelchair and equipment provision affects employment. She argued that these services form part of the national employment infrastructure because many disabled people cannot access or sustain work without the right equipment.

Baroness Lane-Fox stated: “We often file wheelchair and CES services under health and social care; in reality, they ought to be part of our national employment infrastructure.  When services fail, people don’t just lose their mobility, they lose their ability to contribute.”

Delays and unsuitable equipment prevent people from accepting job offers, participating in education, or contributing to the workforce. 

Lord Rennard expanded on this point, stating: “Fundamentally, what we need to address is balancing the costs of the provision of wheelchairs and community equipment with long‑term benefits including preventing accidents, reducing the need for health care intervention in future, enabling people with disabilities to work, pay taxes, and reduce their dependency on benefits, whilst at the same time significantly increasing emotional wellbeing for many families.”

Suitability and modernisation of equipment

Concerns were raised about outdated or unsuitable NHS‑provided wheelchairs. Several peers noted that many commonly issued models remain heavy, steel‑framed, and difficult to transport, contrasting them with modern lightweight designs.

Assessments were criticised for failing to consider lifestyle, employment, and daily activity needs; in some cases, users were forced to purchase their own equipment. Baroness Brinton recounted her own experience of being deemed ineligible for an electric chair despite clinical advice, ultimately having to privately fund her own wheelchair.

Structural issues in contracting and supply chains

Baroness Brinton and Lord Rennard highlighted structural weaknesses in commissioning and procurement. The APPG for Disability Equipment recommended more strategic commissioning practices, better alignment between local authorities and ICBs, and improved oversight to ensure service continuity and quality.

The APPG report identified additional challenges:

• Staff shortages, particularly occupational therapists
• Supply chain constraints and recycling delays
• Lack of strategic commissioning across local authorities
• Limited transparency on waiting times and provider performance

These issues undermine quality, consistency, and long‑term service sustainability, with direct implications for both users and providers.

Calls for a national strategy

Across the House, peers argued for a national strategy to address variation, modernise equipment provision, improve commissioning, and introduce clearer accountability. Suggestions included national leadership and oversight, standardised eligibility and quality criteria, a shift from lowest‑cost procurement to value‑based procurement, and long‑term investment to support modernisation and prevent system fragility.

Lord Hunt argued that many issues could be resolved with national coordination, while Lord Shinkwin and others warned that current failures represent a false economy.

Government response

Responding for the UK Government, Baroness Merron acknowledged the problems described but emphasised that responsibility for commissioning wheelchair and community equipment services lies primarily with ICBs and local authorities.

She stated that there are no plans to publish a national strategy for wheelchair provision. Instead, she pointed to existing frameworks such as the Wheelchair Quality Framework, the NHS 10‑year health plan, and Personal Wheelchair Budgets, which are intended to support local improvement.

Baroness Merron acknowledged persistent delays, citing pandemic‑related backlogs and fluctuating referral rates. She highlighted requirements for ICBs to reduce waiting times over 18 weeks and eliminate 52‑week waits, with performance monitored through the Community Health Services Situation Report.

She also emphasised the need for integrated working between ICBs and local authorities, stating that improvements must be driven locally through existing structures rather than through a new national strategy.

The latest NHS Supply Chain (NHSSC) supplier webinar, held on 3 December 2025, provided essential updates for suppliers on cybersecurity compliance and sustainability expectations. The session, part of NHSSC’s regular information series, featured speakers from its Cyber Security and Sustainability teams, offering insight into upcoming requirements that suppliers will need to meet to remain eligible for tenders and contracts.

Cyber security requirements for suppliers

Jennie Lewis, Cyber Security Compliance Coordinator at NHS Supply Chain, led the session’s opening presentation on supplier cybersecurity. She outlined NHSSC’s adoption of the UK Government’s Procurement Policy Note (PPN) 014, which sets out new baseline security expectations for all suppliers in scope.

All suppliers handling personal information or providing ICT systems and services will be required to demonstrate compliance with Cyber Essentials Plus — a government-backed certification that confirms an organisation has robust cybersecurity controls in place. Certificates must be renewed annually and verified through an external audit. Suppliers can confirm certification validity via IASME, the national accreditation body.

Suppliers processing NHS patient data will also need to complete the Data Security and Protection Toolkit (DSPT), an NHS England-mandated self-assessment to evidence responsible data handling and compliance with information governance standards. For questions on data or security requirements, suppliers can contact cybersecurity@supplychain.nhs.uk.

Where suppliers do not yet hold Cyber Essentials Plus or DSPT certification, NHS Supply Chain has introduced an Information Security Third Party Questionnaire (ISTPQ). This pass/fail assessment, completed at the Supplier Questionnaire stage of a tender, will be reviewed by NHSSC’s Cyber Security Team to assess equivalency to Cyber Essentials standards. NHSSC will take a risk-based approach to non-compliance, weighing the criticality of the product or service against potential cyber risk. However, suppliers without certification may face reduced opportunities for participation in future tenders.

The Cyber Security Team also confirmed that NHS England will be notified of any vulnerable or insecure products or services identified through this process, as part of broader efforts to strengthen supply chain resilience across the NHS.

Evergreen deep dive: sustainability and net zero

The second presentation, delivered by Jade Gaffney, Sustainability Advisor, and Heidi Barnard, Head of Sustainability, explored the Evergreen Sustainable Supplier Assessment, one of five key sustainability criteria suppliers must meet. The “Five Asks” — covering Carbon Reduction Plans, Social Value, the Evergreen Assessment, Horizon Scanning, and Modern Slavery — are central to NHS England’s net zero and sustainability strategy.

From 1 April 2026, all suppliers bidding for new NHSSC tenders will be required to achieve Evergreen Level 1 or above. Level 1 aligns with the Carbon Reduction Plan requirements, meaning suppliers must publicly commit to achieving net zero carbon emissions by 2050 for all scopes. Suppliers unable to meet this requirement will remain eligible for existing contracts but may be excluded from new tenders after this date.

The Evergreen Assessment is hosted on the Atamis platform, accessible under the Information section. NHSSC advised suppliers to ensure their Evergreen submission is correctly linked to their Atamis account to prevent data visibility issues. Annual updates are mandatory, with no automatic reminders issued. Suppliers gathering Scope 3 emissions data should enter “0” placeholders where figures are unavailable, ensuring the assessment remains complete. Queries about sustainability assessments can be directed to sustainability@supplychain.nhs.uk.

The Evergreen framework supports NHSSC’s goal of embedding environmental accountability throughout its supply base, ensuring that procurement decisions contribute directly to the NHS’s wider sustainability and net zero commitments.

The British Healthcare Trades Industry Awards returned in style on 4 December 2025, bringing together organisations from across the healthcare and assistive technology sectors for an evening of recognition, pride, and celebration in the heart of Sheffield.

With a sold‑out room at the prestigious Cutlers’ Hall, a buzzing atmosphere, and a brilliant host in Dr Phil Hammond, this year’s awards showcased the incredible dedication, compassion, and innovation driving our industry forward.

A night to celebrate the very best in healthcare and assistive technology

Guests were welcomed by David Stockdale, Chief Executive of the British Healthcare Trades Association (BHTA), who opened the evening with heartfelt thanks to nominees, judges, sponsors, and attendees. His message set the tone for the night: recognising the exceptional commitment and skill behind every submission and celebrating the people and organisations working tirelessly to improve lives every single day.

Dr Phil Hammond then took to the stage, bringing his trademark humour and warmth, keeping the energy high and the room laughing as the awards got underway.

A huge thank you goes to our event sponsors, including headline sponsor Verlingue, a long‑standing supporter of our work and which offers the BHTA member insurance scheme. We also thank our category sponsors P3 People Management and Foundations for helping make this year’s event possible.

With a three‑course dinner, three rounds of awards, a charity raffle in support of Sheffield Young Carers, and a DJ closing the night, the evening was a true celebration of collaboration, community, and excellence.

The British Healthcare Trades Industry Awards 2025 winners

Below is a full round‑up of the outstanding winners recognised at this year’s British Healthcare Trades Industry Awards 2025.

Rising Star Award

Winner: Liam Bembridge – Gainsborough Healthcare Group
Highly Commended: Brandon Williams – Stiltz Homelifts

The Rising Star category shone a spotlight on exceptional emerging talent. Brandon Williams was recognised for his leadership, technical skill, and the measurable improvements he has driven across his team.

The overall winner, Liam Bembridge, impressed judges with his ability to fuse hands‑on expertise with innovative thinking, strengthening Gainsborough’s reputation for quality while inspiring those around him. A truly deserving Rising Star.

Outstanding Community Outreach

Winner: Ross Care

Ross Care captured this award through its transformative Community Health & Engagement programme, which blends advocacy, education, and compassionate support. Judges were particularly impressed by its holistic approach and the lasting social impact it is creating across the communities it serves.

Best UK Trade Show

Winner: The Occupational Therapy Show

Voted for by BHTA members, The OT Show stood out for its exceptional organisation, strong educational content, and the collaborative spirit it fosters. Bringing together thousands of professionals, it continues to be a cornerstone event for the health and care community.

Manufacturer of the Year

Winner: Raybloc

Raybloc impressed the judging panel with its relentless commitment to innovation and product excellence. The manufacturer’s advanced smart‑glass technology, LED‑lit warning systems, and dedication to quality and safety demonstrate leadership in modern manufacturing, underpinned by meaningful community engagement and an education‑first mindset.

Innovation in Sustainability

Winner: H&M Bathlifts

H&M Bathlifts was recognised for the sustainability‑focused design of the Kanjo Bathlift, championing environmental responsibility without compromising on quality. Its extended warranty model reduces waste, while its recyclable packaging and low‑emission logistics cemented its win as a true leader in sustainable product development.

Product of the Year

Winner: Abacus Gemini MX Bath – Gainsborough Healthcare Group

This award honours products that empower greater independence and dignity. Abacus delivered exactly that through the latest Gemini MX Bath, incorporating direct user feedback into its design. The judges were particularly struck by its impact on children and young people, supported by compelling testimonials demonstrating the real‑world difference it makes to families.

Retailer of the Year

Winner: Wheelfreedom

Although unable to attend the ceremony, Wheelfreedom secured the award thanks to its exceptional multidisciplinary approach, which includes engineers, clinical assessors, and customer service specialists working in tandem. Its robust care cycle, spanning consultation to aftercare, illustrates a deep commitment to customer wellbeing.

Team of the Year

Winner: Medequip’s Wellbeing Team

Medequip’s Wellbeing Team stood out for their proactive, structured, and inclusive initiatives that uplifted their entire organisation. From training more than 90 mental health first‑aiders to expanding neurodiversity awareness and driving staff volunteering, the team has embedded a culture of empathy and support, making an admirable, measurable impact.

Lifetime Service Awards

Winners: Stephen Perry and Jean Hutfield

This prestigious category honours individuals whose decades‑long dedication has shaped our sector.

Stephen Perry

With over 43 years of service in mobility and healthcare, Stephen has been a driving force for innovation, accessibility, and ethical practice. His work across organisations – including Keep Able, Freerider UK, and Electric Mobility – and his later leadership at the BHTA have left a profound and lasting legacy.

Jean Hutfield

Jean’s 50‑year career, including four decades in community equipment, has transformed understanding and recognition of equipment services across the UK. Her influential leadership as Chief Executive and long‑standing Chair of NAEP has strengthened partnerships, professional standards, and patient outcomes nationwide.

Both winners embody the spirit of service, leadership, and compassion at the heart of our industry.

Thank you for an incredible evening

A heartfelt congratulations to all of our winners, nominees, and finalists. Each one represents the best of our sector: innovation, dedication, and an unwavering commitment to improving people’s lives.

Our sincere thanks also go to our judging panel, our sponsors, and everyone who attended the 2025 BHTA Awards Evening. Your passion and support are what make this industry so exceptional.

We look forward to celebrating with you again in 2026. Until then, thank you for helping us champion better, safer, and more inclusive healthcare for all.

One year after the launch of the Design for Life (DfL) Roadmap, NHS England (NHSE) and the Department of Health and Social Care (DHSC) have published a joint update highlighting substantial progress towards building a circular economy for medtech by 2045.

With around two-thirds of the programme’s 30 actions now underway and the DfL collaborative more than doubling in size, the past year has marked a significant shift in national focus on sustainability, innovation, and procurement transformation across the health system.

To help BHTA members understand how this work is evolving, this article summarises key developments across the six DfL problem statements that structure the programme.

For background on the initiative and the opportunities it presents for medtech suppliers, you can also read our earlier article: ‘How the Design for Life programme is opening new opportunities for medtech suppliers’.

Leadership and Alignment

DfL has prioritised developing clear direction for the transition to circular solutions. Over the past year:

• A Priority Adoption Working Group, including clinicians, procurement specialists, NHSE and NHS Supply Chain, has assessed more than 50 product areas to identify those most suitable for early transition to reusable alternatives.
• NHSE has launched a workstream to tackle the overuse of single-use products where evidence shows they are not required.
• Early staff focus groups have been created to understand the barriers and enablers frontline teams face when adopting circular practices.
• NHSE has collated best‑practice resources from across the system into a new central online repository.
• Seven pilots across England and Wales found both cost and carbon savings, with most also maintaining or improving staff satisfaction.
• The NIHR Innovation Observatory has identified 22 KPI classes to help measure circularity progress.
• At COP30, NHSE and partners published the report ‘Decarbonizing the healthcare supply chain – strategic actions for health systems’, setting out practical actions to reduce emissions linked to procurement.

Behavioural Change

Shifting mindset and culture remains a core focus. This year:

• A joint DHSC–NHSE behavioural change team has been established and will launch a stakeholder working group early next year.
• Three key enablers of reusable adoption have been identified: system‑level governance, standardised guidance, and accessible evidence.
• A full literature review has been completed to assess equalities considerations, ensuring circular options are accessible for all patients.

Commercial Incentivisation

Work to embed circularity into procurement and commercial frameworks has accelerated:

• New value‑based procurement guidance, including circularity questions, is being piloted with nine procurement teams and will support upcoming NHS Supply Chain frameworks.
• Circularity criteria have been added to the new assessment framework for community prescribing (Part IX drug tariff).
• Research into servitisation models, including digital twin applications, is underway.
• A series of market engagement sprints is assessing commercial barriers and supplier readiness.

Regulations and Standards

DfL has focused on identifying regulatory barriers that may hinder circular solutions:

• A national survey of suppliers has gathered evidence on remanufacturing of Class I devices to understand where regulations may need to evolve.
• Work has begun on developing national Infection Prevention and Control (IPC) guidance for reuse, supporting safe implementation of reusable products.

Physical and Digital Infrastructure

Building the infrastructure required for a circular medtech system is now a key priority:

• A call for providers to deliver a national review of decontamination capacity has closed and is being assessed.
• Research into current and future decontamination service models—including automation and UV—is underway.
• A joint project with the University of Exeter is analysing material recovery opportunities across high‑value product categories.
• The EPSRC‑funded Digitally Enabled Circular Healthcare Innovation (DECHI) programme has launched to explore how data and digital tools can support circularity.
• The REHEAL programme is underway across several European countries to develop data systems that support circular supply chains.

Transformative Innovation

DfL continues to build the research and innovation pipeline that will underpin future circular solutions:

• SUSTAIN, a sensor‑integrated simulated operating suite at Leeds General Infirmary, is being developed with DHSC funding.
• Seven new research projects worth more than £18 million have commenced.
• A major research convening event brought together 25 circular medtech projects to explore collaboration opportunities.

Looking ahead

Over the next three years, DfL will move from research and insight towards delivering tangible tools, standards, and frameworks to support system‑wide adoption of circularity. Five new working groups, covering behavioural change, commercial strategies, regulation and standards, physical infrastructure, and research coordination, will help guide this next phase.

The DfL website will continue to provide updates, and BHTA will share further information with members as new resources, guidance, and opportunities become available.

The Scottish Government has set an ambitious target for the nation’s life sciences sector — to achieve £25 billion in turnover by 2035. Its newly published ‘Life Sciences Strategy for Scotland: 2035 Vision’ outlines a roadmap for growth built on collaboration, innovation, and sustainable manufacturing.

For BHTA members operating in the life sciences and medical technology sectors, this strategy highlights several areas of direct relevance — from health technology development, to advanced manufacturing, and closer NHS collaboration.

Launching the strategy, Scottish Government Business Minister Richard Lochhead said: “Our ambition is to make Scotland’s life sciences industry the best in the world. With a highly skilled workforce, world-class research base, and an already thriving ecosystem, this strategy provides the framework to deliver sustainable economic growth while improving health outcomes.”

A growing and diverse life sciences landscape

The Scottish Government defines the life sciences sector broadly, covering human, animal, microbial, and plant sciences. Many of these areas overlap directly with the expertise of BHTA members involved in medical devices, digital health, assistive technologies, and healthcare manufacturing.

Key growth areas highlighted in the strategy include:

• HealthTech – covering the design and manufacture of medical devices, diagnostic tools, digital health solutions, and software. Examples include imaging systems, AI-driven diagnostics, wearable monitoring devices, and patient care technologies.
• Advanced Manufacturing – embedding sustainable and digital production methods across life sciences, supported by innovation centres such as the Medical Device Manufacturing Centre, and the Medicines Manufacturing Innovation Centre.
• Digital, Data, & AI – the creation of AI Scotland, a new national body to coordinate artificial intelligence initiatives and accelerate innovation in health and MedTech, including an SME adoption programme.
• Industrial Biotechnology – sustainable materials and processes with applications in wound care, implants, and drug delivery systems, aligning with Scotland’s wider net-zero ambitions.

These sub-sectors form a strong foundation for Scotland’s “Northern Star” network of life sciences clusters, spanning centres in Glasgow, Edinburgh, Dundee, and Aberdeen, with innovation hubs across the Highlands and Islands. Each region contributes to a nationwide ecosystem supporting manufacturing, digital health, and R&D collaboration.

Opportunities for collaboration and innovation

For BHTA members — especially medical device manufacturers and healthcare technology providers — several initiatives within the strategy are particularly relevant:

• Regional Innovation Hubs – Three NHS-led hubs will support Scottish SMEs in testing, validating, and scaling innovative technologies aligned with NHS priorities. This could streamline pathways for BHTA members to bring products into clinical use.
• Accelerated National Innovation Adoption (ANIA) Pathway – A mechanism to assess and adopt transformative medical technologies at scale across NHS Scotland, offering a faster route to market for approved innovations.
• Cluster Development Organisation – A new industry-led body will coordinate Scotland’s life sciences network, fostering collaboration between academia, businesses, and government.
• Infrastructure and Lab Space Expansion – Planned investment will address capacity constraints for start-ups and manufacturers by developing new laboratory, and production facilities across key Scottish regions.

These initiatives collectively aim to strengthen the connection between innovation, regulation, and adoption — helping manufacturers translate new ideas into accessible products that improve patient outcomes.

Additional areas of relevance to BHTA members

The strategy also places a strong focus on areas that align closely with the priorities of BHTA members:

• Integration with the NHS – Through initiatives like Scotland Innovates and the ANIA Pathway, companies will have more structured routes to engage with the NHS. This is particularly relevant for BHTA members developing devices, assistive technologies, or digital solutions that can improve patient care.
• Sustainability in manufacturing – With Scotland targeting net zero by 2045, the strategy encourages greener production methods, and sustainable design principles. Many BHTA members, particularly those in assistive technologies and mobility equipment, are already advancing this agenda through product innovation and resource efficiency.
• Skills and workforce development – Updated apprenticeship frameworks and partnerships between education and industry will help build the next generation of skilled workers in medical technology and healthcare manufacturing. This focus supports the long-term growth of BHTA member companies.
• Digital health and data use – The establishment of Research Data Scotland and AI Scotland provides new opportunities for members working with digital health solutions, or AI-based devices, to leverage health data ethically and effectively for innovation.

By combining these elements, the strategy sets the stage for a more connected, data-driven, and sustainable life sciences sector — one in which medical device and technology manufacturers play a vital role in driving innovation and improving health outcomes across Scotland.

On 26 November 2025, Chancellor of the Exchequer Rachel Reeves presented the Autumn Budget, setting out measures that will affect healthcare and assistive technology businesses across the UK. Below, the BHTA outlines the announcements most relevant to members.

Tendo has also summarised the key announcements from the Budget on behalf of the BHTA. Download Tendo’s overview here.

National Minimum Wage increases

From 1 April 2026, the National Living Wage will rise from £12.21 to £12.71 per hour. The National Minimum Wage for 18 to 20-year-olds will increase from £10 to £10.85.

BHTA recognises the importance of supporting lower-income workers; however, these increases may place additional financial strain on members, particularly smaller companies and those working under fixed-price contracts with the NHS and local authorities, where there is little scope to recover these costs.

Changes to business rates

From 1 April 2026, business rates bills in England will be updated following a 2026 revaluation. The small business multiplier will fall to 43.2p, and the standard multiplier to 48p, in 2026–27.

The government will also introduce two permanently lower retail, hospitality, and leisure (RHL) multipliers for eligible properties with rateable values below £500,000, set at 38.2p for the small business rate and 43p for the standard rate. A high-value multiplier of 50.8p will apply to properties with rateable values of £500,000 and above.

To help businesses adjust, Transitional Relief caps will limit annual increases in bills, with lower caps for smaller properties and higher caps for larger ones. For example, properties with rateable values up to £20,000 (£28,000 in London) will see increases capped at 5 percent in 2026–27, while properties over £100,000 could see rises of up to 30 percent before tapering down.

Additional support will include a one-year Transitional Relief supplement of 1p for ratepayers not receiving Transitional Relief or the Supporting Small Business scheme. From April 2026, the 2026 Supporting Small Business scheme will cap bill increases for the smallest businesses losing small business rates relief or rural rate relief at £800 or the relevant transitional cap, and will support those losing RHL relief for three years. The 2023 Supporting Small Business scheme will be extended for one year in 2026–27.

Most BHTA members are likely to see some increase in business rates from April 2026. The greatest impact is expected for members operating large warehouses, manufacturing sites, distribution centres, or high-value premises where revaluations are likely to push bills higher. Retail-focused members with premises below £500,000 may benefit from the lower RHL multipliers, and smaller businesses losing existing reliefs will receive some protection through the Supporting Small Business schemes.

Apprenticeship funding for SMEs

The Chancellor announced £725 million for the Growth and Skills Levy to support apprenticeships, including a commitment to fully fund SME apprenticeships for eligible people under 25.

This represents an opportunity for BHTA members to bring in new talent and support the development of the healthcare and assistive technology workforce. The BHTA welcomes this investment in skills, particularly as many members have reported sustained cost pressures in recent years.

Electric Vehicle Excise Duty

From April 2028, a new mileage-based Electric Vehicle Excise Duty will require electric and plug-in hybrid drivers to pay per mile alongside standard Vehicle Excise Duty. Electric cars will pay half the petrol and diesel rate, and plug-in hybrids will pay half of the electric rate. The government will also provide 100 percent business rates relief for 10 years on separately assessed electric vehicle charging points and electric vehicle-only forecourts.

For BHTA members using electric or plug-in hybrid vehicles, the new duty will increase running costs, particularly for high-mileage or multi-vehicle fleets. Members investing in charging points may benefit from the 10-year business rates relief on charging infrastructure.

The BHTA’s response

David Stockdale, Chief Executive of the British Healthcare Trades Association, said: “For our members, this Budget is a mixed picture.

“The uplift to the National Living Wage, the commitment to fully fund SME apprenticeships, and some targeted business rates relief are positive in principle, but they sit alongside higher wage bills, rising rates for many industrial sites, and ongoing uncertainty in the wider health and care system.

“Ahead of the Autumn Budget we called for fair and sustained investment in community equipment and wheelchair services, greater funding for home adaptations, and the removal of VAT on public access defibrillators. None of these priorities have been addressed; in particular, the failure to scrap VAT on defibrillators is a missed opportunity to support thousands of local fundraising groups and make lifesaving equipment more affordable in communities across the UK.

“We will continue to work with ministers, officials, and parliamentarians to press for fair funding, a sustainable commissioning model, and the removal of barriers such as the defibrillator tax so that BHTA members can keep delivering the products and services that people rely on every day.”

NHS Supply Chain (NHSSC) has confirmed the approval of its Modernisation Programme, a multi-year initiative designed to update and strengthen its operations across procurement, logistics and supply management. Alongside this, it has introduced a set of Buying Principles that outline how it will approach purchasing decisions and work with suppliers.

Modernisation Programme overview

The Modernisation Programme is structured to enhance the organisation’s commercial capability, update procurement systems, and support improved product and service pathways. According to NHSSC, the programme will involve strengthening digital tools, improving processes, and supporting greater consistency across procurement activities. It is intended to ensure that procurement is more efficient, transparent, and aligned with national objectives.

NHSCC says that the Modernisation Programme will enable it to make a step change in its ability to serve the NHS and patients across England, by investing in IT and supply chain infrastructures through a multi-year programme.

Andrew New, Chief Executive Officer of NHS Supply Chain, commented: “This investment will be used to grow the value of our procurement and delivery services to meet the needs of all of our service users and stakeholders in a resilient and modern system-centric way.

“It will also enable us to address our critical IT resilience risks, as well as delivering our commitment to return a minimum of £1 billion of recurring annual value to the NHS by 2030.”

A short explanatory video released by NHSSC highlights several areas of development within the programme, including improvements to digital infrastructure, enhanced data visibility, and refined systems intended to deliver better outcomes for the wider NHS. The programme is described as a significant step in preparing NHSSC for future demands on procurement and supply management.

Buying Principles

NHSSC has also published its new Buying Principles, outlining the standards and considerations that guide purchasing decisions. These principles state that buying decisions will be evidence-based, transparent, and designed to provide value for money while supporting the needs of the NHS.

The principles include commitments to consistency, fairness, and long-term value, as well as an emphasis on quality and ensuring that procurement decisions contribute positively to patient care. NHSSC notes that the updated approach is intended to improve clarity for suppliers, offering a clearer framework for how purchasing decisions are made.

While the principles are high-level, they directly relate to suppliers by setting expectations for the evaluation of goods and services. NHSSC states that the principles will support more efficient, transparent decision-making and give suppliers greater visibility of the factors that influence category strategies and contracting.

Supplier-related details

The Modernisation Programme states that the new Buying Principles and modernisation activities will help create clearer pathways for engagement with suppliers. The principles indicate that suppliers should expect NHSSC to apply consistent criteria and evidence-based methods during procurement exercises.

The Modernisation Programme includes changes to digital tools and commercial processes that will support enhanced interactions with suppliers. These developments are framed as improvements to the way NHSSC manages sourcing, contracting, and ongoing supplier relationships.

The BHTA joined NHS Supply Chain’s (NHSCC) latest supplier webinar on 12 November 2025 to hear updates on key procurement developments. The session provided practical information to help suppliers understand upcoming changes, maintain compliance with NHS procurement standards, and engage more effectively with NHSCC.

Supplier support on the NHSCC website

Matthew Griffin, Head of Procurement Operations, outlined how NHSCC is helping suppliers adapt to changes brought about by the Procurement Act 2023. A series of new user guides, short videos, and updated website content has been created to make information easier to access. For more information and access to these supplier resources, visit the NHSCC suppliers section.

Matthew also emphasised NHSCC’s increasing focus on cyber security, with new requirements to safeguard systems and sensitive data. A dedicated section on the website provides guidance on meeting these standards. He highlighted the importance of early engagement with the UK Accreditation Service (UKAS) and recommended suppliers familiarise themselves with the Contract and Tender Process pages.

The updated procurement calendar was also noted as a useful tool showing NHSCC’s current and upcoming contract pipeline.

Maintaining accurate information through the Central Digital Platform

Tim Plackett, Performance and Risk Manager, underlined the importance of keeping supplier information up to date within the Central Digital Platform (CDP). Suppliers should ensure their company and product details, including insurance certificates, accreditations, and financial standing, remain current. This supports smoother tenders and contract management.

Tim encouraged suppliers to provide as much detail as possible, stating to suppliers that a good rule of thumb is to assume buyers know nothing about them. He clarified that Supplier Economic and Financial Standing (EFS) is not a pass or fail measure, but it may affect how NHSCC works with individual suppliers.

Category managers can also provide product data extracts at contract level to suppliers, including some information about competitors, though these exclude sensitive commercial information.

NHS Supply Chain Buying Principles

Byron Vincent, Head of Performance and Business Management, presented the Buying Principles, which reflect NHSCC’s commitment to more sustainable, fair, transparent, and effective procurement. The principles form part of NHSCC’s wider modernisation programme and align with national health objectives under the NHS 10-Year Plan.

Centred around three ambitions – Buy Smart, Supply Right, and Partner Expertly – the framework aims to deliver £1 billion in cumulative value to the NHS by 2030. Byron explained that NHSCC will place greater emphasis on value-based procurement, assessing the total value of products and services rather than focusing solely on cost.

The seven buying principles are:

1. Streamline what NHSCC buys and who NHSCC buys from
2. Separate goods from services for clarity
3. Base decisions on system-wide data
4. Simplify and make contracts flexible
5. Support strategic product selection and innovation
6. Buy as one NHS to maximise value
7. Avoid habitual buying and promote continuous improvement

The British Healthcare Trades Association (BHTA) is calling on the UK Government to deliver fair and sustained investment in the healthcare and assistive technology sectors ahead of the Autumn Budget, due to be announced on 26 November 2025.

Support for community equipment and independent living services

The BHTA is urging government to act on the findings of the recent All-Party Parliamentary Group for Access to Disability Equipment report. The report highlights systemic failures leaving thousands without the essential equipment they need. Targeted, long-term investment from the government in community equipment services would ensure that people receive timely support, while reducing pressure on hospitals and enabling more individuals to live independently at home.

Improve wheelchair provision through allocated funding

A recent BBC article exposed widespread delays in NHS wheelchair services, leaving many people waiting months or even years for appropriate equipment. BHTA and industry partners have called for increased funding for Personal Wheelchair Budgets, to ensure individuals can get access to the right chair for their needs.

BHTA members that provide wheelchair services to the NHS are constantly battling underfunding and increased service demand, which impacts their ability to deliver timely, high-quality care. Increased government funding would not only ease this pressure but also enhance the overall efficiency and sustainability of these vital services.

Scrap defibrillator tax

The BHTA continues to lead the national call to remove VAT on public access defibrillators through its Scrap the Heart Restart Tax campaign. This is a simple, cost-effective measure that would immediately make life-saving equipment more accessible in communities across the UK.

The issue is also gaining political momentum, following a recent debate in Parliament where MPs voiced strong support for removing the tax. The association welcomes this cross-party attention and urges the government to act swiftly to implement this crucial reform.

Increase home adaptation funding

The BHTA also calls for greater funding for home adaptations. Evidence from an Age UK report highlights that delays in home adaptations are forcing older people into residential care unnecessarily, demonstrating that timely adaptations help people remain safe and independent in their homes for longer. Increasing Disabled Facilities Grant (DFG) funding would allow more people to access high-quality adaptation equipment suited to their needs – from stairlifts and homelifts to accessible bathing solutions and grab rails – reducing long-term costs for the NHS and social care systems.

David Stockdale, Chief Executive of the BHTA, commented: “We can’t build a fair and sustainable health system without investing in the organisations that make it possible.

“From ensuring access to life-saving defibrillators to funding the right wheelchair for every person in need, these aren’t luxuries – they’re essentials.

“The Autumn Budget is the government’s opportunity to show that it values ethical innovation, fair access, and the health of every individual.”

The British Healthcare Trades Association (BHTA) has welcomed APA Parafricta as a new member, which manufactures garments and bedding to prevent pressure injuries.

The BHTA recently caught up with Claire Cotes, Managing Director at APA Parafricta, to learn more about how the firm’s patented low-friction garments and bedding prevent pressure injuries and how BHTA membership offers valuable advice and guidance on challenges such as net zero compliance and the Drug Tariff Renewal process.

---

A background in finance and business

Claire originally qualified as a chartered management accountant while working at Black and Decker, after completing a business studies degree in Newcastle. After having children, she worked part-time as the office manager for a local builder and then ran her own catering business.  

This background in finance and business led to Claire joining APA Parafricta in January 2020, during covid. She became Managing Director in 2022.

“Working in the healthcare industry has certainly reassured me I didn’t miss my calling as a nurse, and I have nothing but admiration for anyone working in a clinical role,” she added.

Life-changing pressure ulcer prevention products

Claire explained that while most people would, unsurprisingly, assume that pressure ulcers are caused solely by pressure, friction and the associated shearing is actually a big part of the process.

As a manufacturer of garments and bedding to prevent pressure injuries, Claire said that APA Parafricta is the only company to focus on this.

“We developed and patented our unique low-friction fabric, and this is the main component in all of our undergarments, bootees, and bed sheets. We have hospitals who have used the bootees for over 10 years and have never had a hospital acquired heel pressure ulcer whilst using them, so we know they work!”

Claire also commented that she has spoken to tissue viability nurses who have remarked that using APA Parafricta’s undergarments have “literally changed their wheelchair users’ lives” by stopping recurrent pressure ulcers.

“It’s hugely satisfying to know that our products actually make such a difference,” continued Claire. “The products are washable and reusable and are available on FP10.”

How BHTA membership gives access to expert advice and guidance

Claire noted some of the difficulties around net zero demands and carbon reduction plans for SMEs and how the BHTA can support in these areas.

She explained: “Demands for net zero and carbon reduction plans are constantly looming, and the expectation seems to be to spend thousands on consultancy, despite the NHS claiming to be SME-friendly.  I’m very aware of “not knowing what I don’t know” so I hope the BHTA will be useful for that.”

Claire added that BHTA membership was recommended to her by an associate for the purpose of expert guidance through the new Drug Tariff Renewal process.

“When trying to achieve adoption into new hospital trusts, “not invented here syndrome” is a recurring issue, which I know other companies face, and we certainly can’t overcome that issue alone,” Claire added.

Future plans

Looking ahead, APA Parafricta is looking forward to all of the events arranged for Stop the Pressure week (17-21 November 2025). In addition, Claire said that the company is constantly exploring ways to improve its products and make them relevant to a wider audience.

---

To find out more about how the BHTA can support your business and how to become a BHTA member, visit this page.

The Health and Safety Executive (HSE) has launched a call for evidence to review the Lifting Operations and Lifting Equipment Regulations 1998 (LOLER).

The consultation invites input from manufacturers, importers, suppliers, duty-holders, users, and other interested organisations.

The HSE’s review seeks to ensure that the regulations remain effective, proportionate, and aligned with modern technologies. It aims to identify any unnecessary burdens placed on businesses while maintaining the high standards of safety that LOLER helps to ensure. The consultation will examine whether the scope and application of LOLER continue to be fit for purpose and whether updates are needed to reflect new types of equipment, processes, or industry practices.

LOLER applies to any organisation that owns, operates, or supplies lifting equipment, including those involved in the manufacture and use of patient-handling equipment, hoists, slings, and other devices used in healthcare settings.

These regulations require every lifting operation to be properly planned, supervised, and carried out by competent persons using suitable and well-maintained equipment. In many cases, equipment must also undergo regular ‘thorough examinations’, with records retained for inspection — all of which create important, but often resource-intensive, compliance obligations for businesses.

For BHTA members, particularly those manufacturing or supplying patient handling products, this consultation offers an opportunity to share practical insights and evidence about how LOLER works in practice. Manufacturers and suppliers are encouraged to consider whether the current definitions of ‘lifting equipment’ and ‘lifting operations’ remain appropriate in the context of modern assistive technologies.

There may also be scope to comment on whether inspection intervals or reporting requirements could be made more flexible without compromising safety, or whether advances in product reliability and design might justify a more risk-based approach.

The review may also consider how LOLER interacts with other legislation, including the Supply of Machinery (Safety) Regulations and the Provision and Use of Work Equipment Regulations (PUWER). Given the increasing use of powered and automated lifting devices in healthcare environments, the HSE is keen to gather feedback on how the regulatory framework could evolve to reflect innovation while continuing to protect patients and care staff.

The consultation remains open until 11 November 2025. The BHTA encourages all members affected by LOLER, particularly manufacturers and suppliers of patient handling equipment, to take part in this important consultation. Respond to the consultation here.

A new report, published today by the All-Party Parliamentary Group (APPG) for Access to Disability Equipment, reveals a national crisis in community equipment services.

The BHTA and Newlife, supported by Tendo, helped parliamentarians launch the APPG for Disability Equipment Access. The BHTA continues to support the APPG for Access to Disability Equipment.

The new report details findings from the APPG’s inquiry into community care equipment and barriers to access.

Community equipment provides children, adults, and elderly people with disabilities or temporary care needs with often vital equipment, such as harnesses, grabrails, and hoists. However, the report has found that almost three-quarters of people feel that systems providing community equipment is not meeting their needs.

According to the report, the crisis is leaving thousands of vulnerable people without the essential medical equipment they need to live safely and independently. The summer-long inquiry found the issue is systemic. The sector is unable to innovate and is held back by a creaking system, carers are unable to dedicate sufficient time towards patients, and patients themselves reporting the system simply does not work for them.

The report has found evidence of users waiting months and sometimes years for critical care assessments and access to critical medical equipment.

Entitled ‘Barriers to Accessing Lifesaving Disability Equipment’, the report found that:

• Over half of equipment users do not have the medical equipment they need for their long-term needs.
• 63 percent of carers and 55 percent of users say services are getting worse.
• 74 percent of equipment providers said they were aware of patients experiencing delayed hospital discharges.
• 44 percent of equipment providers say community equipment provision is “not at all consistent and equitable.”
• A third of equipment users reported that they are still waiting to receive approved equipment.
• Many families reported having to purchase their own equipment, with further widespread reports of users being let down by the current system.

Commenting on the report findings, David Stockdale, Chief Executive of the BHTA, said: “This report exposes the long-term, systemic challenges that those of us in the sector have been raising for years.

“The entire sector is committed to ensuring people have access to safe, high-quality equipment when they need it, but the lack of national oversight, inconsistent local commissioning, and insecure funding are undermining that goal.

“We urgently need a coordinated national approach that provides clear accountability, consistency across local areas, and robust, long-term investment. This report should serve as a catalyst for reform, ensuring the essential services that so many rely on are properly supported, resourced, and fit for the future.”

The APPG inquiry that fed into the report ran between July and September 2025. It has uncovered widespread evidence of systemic and in many cases unsafe delays.

The report found the crisis is in part caused by regional inequalities and the lack of national accountability, direction, and leadership. It concludes that long-term systemic fragmentation, underinvestment, and absence of political leadership are leaving vulnerable people and their families without the basic tools they need for dignity and independence.

To tackle the crisis, MPs on the APPG are calling on the UK Government to work with patients, carers, and industry to launch a dedicated strategy for community care equipment, overseen by a named Minister with clear responsibility for its delivery.

Launching the report in Parliament today, Daniel Francis MP, Chair of the APPG, said: “Across hundreds of testimonies, one message came through loud and clear: the system designed to support disabled children and adults is failing them. It is failing to deliver equipment on time, failing to provide the right support, and failing to listen to the very people it exists to serve.

“Under the current system we’re seeing children missing school, adults being forced out of work and carers injuring themselves. It’s failing patients, carers, and the sector alike, and it’s high time for the Government to get a grip.

“Access to community equipment is not privilege, it’s a daily necessity. We need a National Strategy for Community Equipment and clear leadership and accountability in its delivery. Ensuring everyone is given the right support at the right time is simply a matter of political will and commitment.”

The inquiry heard from 626 survey respondents, including equipment users, parents, carers, professionals, and suppliers. Many described a system that “barely scrapes the barrel of what people actually need to live their everyday lives”.

One equipment user told the APPG: “The delay has disabled me more and had a really negative impact on my mental health.”

Another parent said: “My child is being stunted by unsuitable equipment, missing vital years of development.”

Key report recommendations to government include reform funding and commissioning to focus on quality, not just cost, and support sustainable innovation, alongside reduce waiting times and delays through workforce investment and better coordination between the NHS and local authorities.

In addition, the report suggests that the government improves communication and transparency with families and carers through a national framework and central data monitoring; strengthens reuse and recycling systems so equipment no longer sits unused while others go without; and creates a National Advisory Board to give equipment users and carers a real voice in service design and delivery.

Click here to read the full report.

The British Healthcare Trades Association (BHTA) has welcomed Urathon as a new member, which provides high-quality community equipment that helps people live more independently and comfortably.

The BHTA recently caught up with Lucy Carson, COO & Finance Director at Urathon, to learn more about the firm’s commitment to quality community equipment; future plans; and the value it sees in joining the BHTA’s trusted network that offers industry support, shared values, and opportunities for collaboration and development.

---

Bringing varied finance and accounting expertise to Urathon

Lucy has gained experience across a diverse range of industries, from working with a company that owned a chain of 150 pubs and clubs, to a large corporate wire and cable manufacturing business, and more recently, a small local printing firm.

“My roles have always been rooted in finance and accounting, giving me a strong understanding of both large-scale operations and close-knit, community-driven businesses,” she explained.

Making a difference in the community

Urathon is a community equipment provider that works with local authorities, healthcare providers, and retail partners to make sure its products truly meet the needs of the people who use them.

“Our focus has always been on quality, innovation, and care — making a real difference in everyday life,” Lucy said.

Urathon recently welcomed two university graduates to the team, who are helping elevate the provider’s marketing and social media presence while also supporting sales efforts. Lucy enthused: “It’s been great bringing in some fresh ideas and energy!”

Why being a BHTA member is synonymous with being part of a valued network

Lucy explained when she came across the BHTA: “I first heard about the BHTA when I saw all the fantastic support they were offering following the collapse of NRS, and it really highlighted how valuable the association is to our industry.

“It showed me that the BHTA isn’t just about membership — it’s about community, guidance, and standing together as a sector.”

For Urathon, being a BHTA member means that the company is part of a trusted network that shares its values of quality, integrity, and professionalism.

The BHTA also provides timely access to industry insights, best practices, and networking opportunities that are not available elsewhere, which will all help Urathon grow and continue improving the services it offers to customers.

Event presence and exciting product launches

Urathon will be attending the OT Show for the first time this year and has just secured a bigger stand.

On 4 December, Urathon will be attending the British Healthcare Trades Industry Awards 2025, which provides an excellent opportunity to network and celebrate the healthcare industry’s success.

Urathon also recently achieved ISO 9001 accreditation, which is a huge milestone for the company and Lucy’s team.

Looking ahead, Urathon is excited to be launching some new and innovative products for the retail sector in 2026. The firm will be attending Naidex again next year with an even bigger stand.

Lucy also has a big aspiration for Urathon next year: “My goal is for Urathon to be nominated for a BHTA Award in 2026.”

---

To find out more about how the BHTA can support your business and how to become a BHTA member, visit this page.

The NHS is strengthening its commitment to innovation and efficiency through the introduction of new value-based procurement (VBP) standards for medical technology.

The Department of Health and Social Care (DHSC) has published the ‘Value Based Procurement Standard Guidance for Medical Technology’, designed for use within the NHS’s 13 VBP pilots. Although the guidance has been created to support these pilot projects, it also provides valuable insights and practical applications for the wider medical technology sector.

The guidance is intended for use by both NHS buyers and suppliers to help assess not only the cost of medical devices but also the broader value they deliver to patients, staff, and the healthcare system.

This shift towards value-based decision-making comes alongside the government’s announcement that the NHS will invest in pioneering technology to help reduce waiting lists and improve productivity across services. Together, these initiatives aim to ensure that procurement decisions increasingly reward technologies that demonstrate measurable improvements in outcomes, efficiency, and sustainability.

A holistic approach to procurement

The new DHSC guidance establishes a framework for evaluating medical devices across five domains: social value, efficiency, patient and staff outcomes, supply chain resilience, and purpose. A sixth factor, whole-life cost, complements these domains by ensuring that price is considered within the broader context of lifecycle value.

Under the new framework, NHS buyers are encouraged to assess tenders not solely on upfront cost but on the overall contribution a product or service makes to the health system.

Each domain can be weighted according to the needs of a particular procurement, but social value must account for at least 10 percent of the total weighting, in line with the NHS Social Value Playbook. Overall, at least 60 percent of procurement scoring must relate to the value domains, while whole-life cost is capped at 40 percent.

This marks a step away from purely price-driven procurement and towards a model that prioritises long-term outcomes, sustainability, and patient benefit.

Measuring value across domains

Each of the five value domains provides a structured set of questions and evaluation criteria for buyers and suppliers. The social value domain encourages suppliers to demonstrate how they will reduce carbon emissions, manage modern slavery risks, or improve sustainability in packaging and disposal. The efficiency domain considers how a product can simplify patient pathways, increase hospital or community productivity, and support accurate measurement of outcomes. The patient and staff domain emphasises safety, patient experience, and health equity, while supply chain and purpose focus on resilience, interoperability, and ease of use.

Suppliers are expected to provide measurable, evidence-based responses that show how their technologies can deliver tangible improvements. This includes providing baseline data, real-world evidence, and models that quantify benefits such as reduced complications, improved patient satisfaction, or optimised workforce time.

Supporting the NHS’ wider transformation goals

The guidance is part of a wider shift within the NHS towards integrating innovation, sustainability, and productivity.

Andrew New, CEO of NHS Supply Chain, said: “Innovative technology has a vital role to play in delivering faster, simpler and more effective care for patients. Through this new approach, we can ensure that procurement not only secures the best value for money but also supports the NHS in achieving its long-term goals around efficiency, sustainability and patient outcomes.”

Implications for suppliers

BHTA member companies supplying medical technology to the NHS will need to engage more deeply with buyers to demonstrate measurable value through data, evidence, and partnership. This includes clearly articulating how their products support clinical efficiency, improve patient experience, and align with NHS sustainability objectives.

The framework also highlights the importance of collaboration between suppliers, clinical teams, and procurement professionals. Bidders are encouraged to provide evidence that supports their claims, including quantitative data, modelling, and independent validation where possible.

The guidance advises buyers to ensure proportionality in their tender requirements to support the participation of small and medium-sized enterprises (SMEs) within the medtech sector.

Suppliers may wish to focus on areas such as:

• Demonstrating carbon reduction and sustainable manufacturing practices;
• Providing evidence of improved efficiency and productivity outcomes;
• Showcasing innovations that reduce risks to patients or staff;
• Supporting equitable access and addressing health inequalities;
• Building resilient and transparent supply chains.

By preparing evidence-rich submissions aligned to the five value domains, suppliers can better position themselves to succeed in NHS tenders under this new approach.

A shared vision for sustainable innovation

The VBP guidance underscores a wider movement within the healthcare system towards smarter, more sustainable procurement. As the NHS aims to make better use of technology to enhance care delivery, these frameworks are helping to ensure that procurement decisions reflect genuine long-term value.

Andrew added: “By focusing on value rather than volume, we are creating the conditions for innovation to thrive — enabling suppliers to bring forward solutions that improve outcomes for patients and deliver efficiencies for the NHS.”

---

Download the full value-based procurement guidance here.

The UK Government has announced enhanced collaboration between the Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).

The collaboration is intended to accelerate innovation, strengthen patient safety, and reduce barriers to transatlantic market access for medical technologies and AI.

Key developments

The MHRA will deepen its regulatory collaboration with the FDA, with a shared ambition to advance alignment and reciprocity.

During the Advanced Medical Technology Association conference in San Diego, MHRA Chief Executive Lawrence Tallon highlighted the agencies’ commitment to accelerating joint initiatives and policy development, supported by strategic opportunities for cooperation.

The MHRA has launched the National Commission on the Regulation of AI in Healthcare, bringing together UK and international experts, including contributors from the United States. The commission will develop recommendations to support the safe and transparent use of AI-driven medical technologies and to contribute to international alignment.

The agency has also confirmed plans for new international reliance routes designed to improve international investment and increase UK access to medical devices that have already been approved by trusted regulators, including the FDA.

According to the announcement, the reliance framework is intended to include products cleared through the FDA’s 510(k), De Novo, and Premarket Approval (PMA) pathways.

What this means for BHTA members

For BHTA members operating in the UK and internationally, the planned international reliance routes are expected to facilitate faster UK market access for devices already approved by trusted regulators.

The strengthened collaboration between the MHRA and FDA, together with the establishment of the National Commission on the Regulation of AI in Healthcare, signals ongoing work to align approaches to regulating medical technologies and AI.

The medtech regulatory reforms in Great Britain are intended to enter legislation in 2026  and open new reliance routes from 2027.

Background

The Medicines and Healthcare products Regulatory Agency (MHRA), working with the Department of Health and Social Care, ran a call for evidence to inform its statutory review of the UK medical device regulatory framework.

The consultation received 123 responses from industry, trade associations, healthcare professionals, patient groups, and charities. To learn more about the consultation and see the BHTA’s full response, read this article.

As part of this work, MHRA held a workshop with trade associations, including the BHTA, to share early analysis from the responses and invite further input from stakeholders.

Survey results

The figures below summarise the initial responses from stakeholders to the MHRA consultation.

When asked – How well do you think the current UK medical device regulatory framework protects public health? – most felt it offers protection to some degree, with 40 percent selecting ‘somewhat effectively’ and 35 percent ‘effectively’. A further 12 percent said ‘very effectively’. Five percent answered ‘ineffectively’, and seven percent were ‘not sure’.

To the question – On a scale where 1 = not at all effective and 10 = extremely effective, how effective are the regulations in practice? – scores clustered in the mid‑to‑high single digits, with the largest share around six to seven, and relatively few at the extremes. This indicates a broadly moderate view of day‑to‑day effectiveness.

See the slide below for views on unnecessary or excessive regulatory burdens and whether stakeholders have encountered any issues, blockers, or areas of ambiguity when using the regulations.

To the question – On a scale where 1 = not at all clear, well‑structured, or easy to navigate, and 10 = extremely clear, well‑structured, and easy to navigate, how would you rate the framework? – responses typically centred around six, with relatively few at the extremes.

When asked “Are there any overlapping, duplicative, or outdated provisions in the framework?”, 47 percent said ‘yes’, 42 percent ‘no’, and nine percent were ‘not sure’.

Views were cautious when asked: “Do the regulations provide the appropriate balance of flexibility to respond to new technologies or emerging public health issues, and robust regulatory oversight?” 42 percent disagreed and 11 percent strongly disagreed; 27 percent neither agreed nor disagreed; 17 percent agreed; and two percent strongly agreed.

Responses to the question – Do you think the current balance between what is set out in legislation and what is provided in supporting guidance appropriate? – received mixed responses. 19 percent answered ‘yes’. 28 percent felt too much sits in legislation, 21 percent felt too much sits in guidance, and 42 percent were unsure.

See the slide below for stakeholders’ views on streamlining medical device legislation.

BHTA’s contribution

On behalf of member companies, the BHTA welcomed MHRA’s engagement and added two pragmatic suggestions in the session:

• Increased funding/resource allocation for “human at the end of the phone” resources to deal with industry queries that fall between MHRA’s guidance webpages (existing) and paid-for consulting services of MHRA (future, envisioned as part of MHRA’s enhanced functionality once the changes to regulations are out of the way); 
• Face-to-face sessions to discuss complex issues, e.g. how – in MHRA’s envisioned International Reliance routes – MHRA will divide labour between itself (as the regulator) and UK approved bodies & EU notified bodies when it comes to approvals, application processes, and technical file examination. 

Next steps

According to discussions with MHRA, there will be further stakeholder workshops in October.

Findings from the survey and these workshops will inform the review, with a report expected early next year; all feedback will be anonymised in the final report.

The British Healthcare Trades Association (BHTA) has responded to a consultation seeking views from relevant stakeholders about the UK’s medicines and medical device regulatory framework.

Conducted by the Medicines and Healthcare products Regulatory Agency (MHRA), in collaboration with the Department of Health and Social Care (DHSC), the consultation focused on the legislation that govern the development, authorisation, supply, and oversight of medicines and medical devices in the UK. These include the Medical Devices Regulations 2002 and the Medical Devices (Fees) Regulations, which are relevant to BHTA members.

Ahead of the 19 September 2025 deadline, the BHTA invited members to share their views so that they could be included in the BHTA’s response to the consultation.

Read the BHTA’s full consultation response here.

Our response: Operation of the regulations

“We strongly recommend extension of CE‑marked products in perpetuity, beyond the current 2028/2030 transition periods. The economic reality of the UK’s global market position means that patients, clinicians, and large commissioners (the NHS) will benefit most from continued acceptance of CE-marked products (which provides the most effective route to market for global/multi-national companies) AND a clear, robust, well-resourced domestic assurance route for UKCA-marked products (which provides the most effective route to market for UK-based SMEs who supply primarily (or only) the UK market).”

BHTA welcomes the intent of the medical device regulations but notes that recent uncertainty has affected companies and, ultimately, patients. Members have reported operational challenges stemming from shifting timelines for continued acceptance of CE-marked products, evolving fee structures, and a lack of clarity around the respective roles of MHRA and UK Approved Bodies.

“Businesses need predictability, appropriate advance notice, and clear regulatory pathways in order to invest confidently.”

BHTA’s view is that the regulations are broadly fit for purpose; however, MHRA resourcing and service performance must keep pace with regulatory demands. Increases in fees should be matched by measurable improvements in timeliness and quality of service delivered by the MHRA.

Our response: Fees and cost recovery

“Timely production of indicative fees, well before 01‑Apr‑26, will be essential… [and] quarterly or monthly payment plans for UKRPs… will be essential.”

BHTA recognises MHRA’s work towards an algorithm-based post-market surveillance cost-recovery model using GMDN level 2 categories. To help businesses plan, the association urges early publication of indicative fees well ahead of the model’s commencement on 1 April 2026.

Flexible payment options, such as quarterly or monthly plans for UK Responsible Persons acting for multiple manufacturers, would ease the transition. Any changes should be accompanied by transparent, public performance metrics and consistent delivery.

Our response: Roles and international recognition

Greater clarity is required on the division of responsibilities between MHRA and UK Approved Bodies, particularly as international recognition (IR) routes are developed. BHTA supports IR in principle, but asks for timely, practical guidance on how any additional information will be collected, assessed, and used by the regulator and Approved Bodies, to avoid duplication and delay.

BHTA also advocates for closer alignment with trusted international regulators to reduce duplicative evidence requirements and restore the UK’s attractiveness as a launch market. In this context, the association supports making CE mark recognition permanent for medical devices in the UK without a time limit to stabilise supply chains, avoid unnecessary duplication, and maintain effective access.

“By aligning regulatory procedures and decision-making with international standards, the UK can offer businesses greater predictability, minimize duplication of evidence requirements, and accelerate product entry into the market. We firmly support the continued acceptance of CE-marked medical devices in the UK without a time limit.”

Our response: Excessive regulatory burdens

“The existence of separate legislation for medical devices in Great Britain and Northern Ireland creates an unnecessary burden. Differing requirements and duplicated regulatory submissions add complexity, raise compliance costs, and discourage innovation. This regulatory split can delay the availability of new devices in one or both regions, without delivering any clear improvements in safety or quality.”

In response to the MHRA’s question about unnecessary and excessive regulatory burdens, the BHTA also calls for improved access to expert, ‘actual-human’ advice alongside digital portals, so registrants can resolve complex issues more efficiently without ad-hoc escalation.

BHTA further supports DHSC/MHRA work to enable reuse of appropriate single-use Class I medical devices, where safe, as part of a pragmatic approach to sustainability, cost control, and patient access.

Our response: Legislation versus guidance

“Keeping regulatory detail to a minimum while expanding on it within guidance allows MHRA to respond more rapidly and effectively.”

To keep pace with technology and public health needs, BHTA favours placing more technical detail in guidance rather than in legislation. Guidance can be updated more rapidly, allowing regulators and industry to respond quickly while maintaining safety. The association also encourages early and continuous engagement with stakeholders in the development of guidance, reflecting lessons from the pandemic period when temporary flexibilities were introduced without major issues.

Our response: New regulations made under the Medicines and Medical Devices Act (MMDA)

“The shift to a cost‑recovery model occurred while MHRA was dealing with significant backlogs… any fee increases should be accompanied by more consistent and prompt delivery of MHRA services.”

The BHTA has engaged with several statutory instruments made under the Medicines and Medical Devices Act, including changes to fees and extensions for CE-compliant devices in Great Britain. Operation to date is assessed as ‘somewhat effective’. However, the shift to cost recovery coincided with backlogs, underlining the need for clear communication, adequate resourcing, and stronger performance management. Any fee increases should be accompanied by timely services and enhanced staff capability.

Ongoing engagement with the MHRA

“We strongly support MHRA’s recent renewed openness to engagement with industry, and to proactive collaboration.”

The BHTA emphasises that MHRA having ongoing dialogue with industry and patients will help ensure that regulation and guidance are workable, support innovation, and maintain safe access to medical technologies.

The wheelchair sector has responded to a recent BBC news report that highlights how thousands of people across the UK are experiencing long waiting times for crucial mobility equipment, as the NHS faces tighter budgets and higher demand.

In the most recent quarter (January-March 2025) in England, 77.9 percent of children and 80.8 percent of adults received an NHS wheelchair, or a modification to their wheelchair, within 18 weeks. This is below the 92 percent target set out by NHS England.

A large contributing factor to these delays is a lack of funding from the UK Government for vital NHS wheelchair services, which means providers do not have sufficient resources to deliver them effectively and timely.

The Wheelchair Alliance is a community interest company with a goal of improving wheelchair provision in England. Its vision is to transform the experience of wheelchair users in England through improved access, quality, and effectiveness of services.

Nick Goldup, CEO of the Wheelchair Alliance, said: “The Wheelchair Alliance is working hard to ensure people receive better provision of wheelchairs through the NHS, and we often hear of long waits for appointments and receipt of a wheelchair. Wheelchair users are often faced with a complex and complicated system to navigate.

“The NHS refers regularly to the use of Personal Wheelchair Budgets (PWBs) as a mechanism to help people receive the wheelchairs they need; however, these are very limited in their application as the rules often prevent wheelchair users from getting what they want.

“For example, in Ivy’s case, Ivy would benefit from a powerchair but would be prevented by the PWB rules from upgrading her manual chair to powered and, if she decided to take the PWB externally to buy a powered chair, the money offered by the NHS would come nowhere near to how much she would need. This results in an inequality.

“In short, PWBs can be good for people with money, but for those with limited funds they offer no solutions.

“The Wheelchair Alliance is lobbying government for ownership and accountability of wheelchair services at a senior, national level, to take responsibility for a broken system. We have also been working hard towards driving improved commissioning of services through developing a Quality Framework that we hope the NHS will use to make wheelchair provision more consistent and fair.

“Lastly, our research and reports have shown that much of the data around demand for wheelchair services is estimated. We need reliable data to form an accurate local and national picture, as well as improved budgets.”

BHTA member AJM Healthcare has also responded. AJM Healthcare is an NHS wheelchair services provider in the UK, specialising exclusively in wheelchair services.

Guy Eatherington, Business Development & Customer Relations Director at AJM Healthcare, commented: “AJM Healthcare is committed to supporting the ongoing national redevelopment and reform of wheelchair services.

“The data presented below highlights a concerning trend across the system: a significant number of service users are not receiving the equipment they need within appropriate timeframes. This delay in provision undermines both the quality of care and the independence of individuals relying on these essential services.

“One key metric of referrals received versus referrals completed, has shown a peak performance of 97 percent. However, the average completion rate over the past two years stands at just 90.59 percent, indicating a persistent gap in service delivery.

“More than three-quarters of wheelchair services across England are currently delivered by NHS trusts or other publicly funded or third-sector organisations. This reflects the significant role that non-private entities continue to play in the provision of the NHS wheelchair services provision nationwide.

“More critically, the national waiting list has grown substantially during this period. An additional 40,000 individuals have been added to waiting lists across the country, reflecting mounting pressure on services and a growing unmet need.

“AJM Healthcare recognises the urgency of these challenges and remains dedicated to working collaboratively with commissioners, providers, and service users to drive meaningful improvements. Our goal is to ensure that every individual receives timely access to the right equipment, enabling greater mobility, independence, and quality of life.”

David Stockdale, Chief Executive of the British Healthcare Trades Association (BHTA), added: “Stories like this are deeply concerning, and they reflect what our members tell us: demand for NHS wheelchair services is rising, but funding has not kept pace.

“Clinicians and providers work hard within tight constraints; the issue is not a lack of commitment on the frontline, but a lack of sustained, adequate investment. Without funding to meet increasing need and costs, services struggle to recruit, retain, and innovate, and people wait too long for the essential equipment that enables independence, safety, and participation in daily life.

“We urge the government to prioritise wheelchair provision by increasing budgets, setting clear national accountability for delivery, and supporting consistent commissioning so that access is fair across the country. With the right resources, the system can reduce waiting times, provide the right chair first time, and ensure that every wheelchair user receives timely, person-centred support.”

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a call for evidence on how it should prioritise the designation of standards for medical devices in Great Britain, to inform future work under the Medical Devices Regulations (MDR) 2002.

Scope of the call

The exercise focuses on device standards used for medical devices placed on the Great Britain market. It invites views on the current list of designated standards and asks stakeholders to identify further standards that could be considered for future designation.

The MHRA states: “Designated standards are specific standards that have been officially recognised by regulatory authorities in the UK as providing a presumption of conformity with the essential requirements of relevant regulations.

“When a device complies with a designated standard, the device meets relevant essential requirements the standard addresses.”

What the consultation asks

The questionnaire requests factual information on how organisations use device standards in practice, and invites detailed suggestions about the content of the designated list.

Examples include:

• Whether already-designated standards are used to support compliance with MDR 2002, and which of those are used most frequently or are considered most important.
• Whether additional, non-designated standards should be added to the designated list, with fields to specify the standard and provide supporting detail.
• Whether any standards should be removed from the current designated list.
• Whether standards should be replaced with alternatives or updated where newer editions exist.

The survey also asks respondents to rate the practical value of designated standards for market access; for example, whether using designated standards provides time savings in submission and approval processes, and whether mappings to essential requirements are useful.

Context within ongoing reforms

This activity forms part of the MHRA’s wider programme to develop the future regulatory framework for medical devices in Great Britain, aiming to prioritise patient and public safety, maintain access to needed technologies, and support innovation. Input gathered through this exercise will inform how the agency prioritises future work on designation.

Relevance for BHTA members

For organisations engaged in standards and regulatory compliance, the consultation focuses on which medical device standards are relied upon to demonstrate conformity, and where changes to the designated list could improve alignment with current practice. Designated standards remain a recognised route to demonstrating compliance with essential requirements in Great Britain.

The deadline for responses to the MHRA’s open consultation is 30 September 2025. Respond online here.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published an updated response to its consultation on statutory fees for medical devices, confirming that a new annual registration fee to support post‑market surveillance (PMS) activities will take effect from 1 April 2026. This article summarises the changes for BHTA members.

What is changing

From 1 April 2026, an annual medical device registration fee will be charged per Global Medical Device Nomenclature (GMDN) level 2 category under which a manufacturer has registered products. Where no level 2 exists, level 1 will apply.

The MHRA has confirmed that this new fee will replace the current one‑off medical device registration fee and will be calculated on the categories recorded on 1 April each year, with pro‑rata charges for any new categories added mid‑year.

The MHRA has indicated an estimated amount of £300 per category from 1 April 2026 per GMDN level 2 category (or level 1 category where no level 2 exists), and has noted that approximately 60 percent of manufacturers are expected to pay a single charge.

See the updated response, published 2 September 2025, for more information: ‘MHRA consultation on statutory fees — proposals on ongoing cost recovery: updated government response’.

The one‑off device registration fee remains in place until 31 March 2026. Current schedules, including the £261 medical device registration fee, are set out on the ‘Current MHRA fees’ page.

Why the model has changed

In its original consultation, published on 29 August 2024, the MHRA proposed an annual medical device registration charge modelled at £210 per GMDN code to fund PMS activities. Feedback from industry, including trade associations, questioned affordability and fairness across different device portfolios.

The revised approach, set at GMDN level 2, is intended to distribute costs more equitably while maintaining patient safety and supporting innovation. The consultation documents and background are available at ‘MHRA consultation on statutory fees — proposals on ongoing cost recovery’ and in the original consultation paper ‘MHRA consultation on statutory fees’.

How the new fee will be applied

Under the updated model, a manufacturer will pay once per relevant GMDN level 2 category for the charging year from 1 April to 31 March. If additional categories are added during the year, the charge for those categories will be applied on a pro‑rata basis for the remainder of the year.

Before billing begins, the MHRA will invite manufacturers to take part in a data‑cleansing exercise so they can remove obsolete or withdrawn products from the register without charge. Further guidance will be published by the MHRA to explain scope, billing mechanics, and preparation steps, according to the organisation.

The MHRA has stated that fees will continue to be paid through the Device Online Registrations System (DORS). BHTA members should ensure internal payment processes are ready for the new annual billing cycle.

A recent House of Commons debate on defibrillators has brought the life-saving role of these devices into sharp focus, highlighting not only the critical importance of timely access but also the systemic disparities and policy shortcomings that hamper their effective deployment across the UK.

The case for universal access

Survival rates for out-of-hospital cardiac arrests remain shockingly low at around eight percent, yet early defibrillation can increase survival chances to over 70 percent. Access within three to five minutes is often the difference between life and death.

Speakers across all parties agreed that access to defibrillators is a public health necessity, not a luxury. Personal stories, like those of Jack Hurley and Dylan Rich, underscored the real-world stakes. The consensus: every community, regardless of postcode, should have timely access to these vital devices.

MPs also highlighted that not all registered devices are publicly accessible or available 24/7, with many locked in buildings during off-hours. This significantly undermines their potential impact during emergencies. There were calls for better visibility and signage in communities, particularly in schools, workplaces, and public areas.

The postcode lottery: A matter of life and death

One of the most sobering revelations was the sheer extent of regional inequalities. In constituencies like Bishop Auckland, Uxbridge, Rushcliffe, and Wolverhampton North East, more than half of all postcodes are outside the recommended access range for defibrillators.

Rural areas fare especially poorly. Constituents in some parts of North Antrim and Mid Dunbartonshire face 30-minute journeys to the nearest automated external defibrillator (AED). Even within major cities like London and Leicester, significant coverage gaps exist, particularly in deprived or high-density areas.

The debate revealed an urgent need for a national strategy that closes these gaps and ensures equitable access to defibrillators—something especially vital for BHTA members, many of whom serve vulnerable populations.

These disparities were not limited to access alone but extended to equipment quality and functionality. Cases were shared of non-functional defibrillators at critical moments, highlighting the urgent need for nationwide maintenance standards and device audits.

Community heroes and local innovation

Many MPs paid tribute to local charities and volunteers stepping in to fill the void left by insufficient government provision. Initiatives like Southport Saviours, Hearts for Herts, and Lucky2BHere have deployed hundreds of devices, often powered by tireless community fundraising.

Examples such as lamp post-powered defibrillators and bleed control kits integrated into AED cabinets showcased grassroots innovation. Some schools have gone above and beyond by ensuring their defibrillators are accessible to the public at all times—a best practice many hope to see replicated.

However, relying on volunteer efforts is neither sustainable nor equitable. Constituents in well-resourced communities benefit from better access, while those in deprived or rural areas are left behind. This grassroots energy must be matched by national policy support and funding, MPs warned.

Policy gaps and practical solutions

The debate produced a range of pragmatic policy recommendations that align closely with BHTA’s advocacy goals:

• VAT exemption: widely supported across parties, removing VAT on defibrillators and accessories would ease financial burdens on schools, places of worship, and community groups.
• National database improvements: many AEDs are not registered or are locked away during emergencies. MPs called for a real-time, reliable mapping system, like The Circuit, to ensure operational readiness.
• Planning and legal frameworks: ideas included making defibrillators mandatory in new housing developments, public buildings, and even police vehicles.
• Training requirements: several MPs advocated for compulsory CPR and defib training in schools or as part of driving tests, promoting national resilience.
• Maintenance standards: ensuring AEDs are regularly checked and functional was a recurring concern, with tragic consequences when devices fail.
• Tackling misuse and vandalism: there was cross-party support for criminalising the misuse or destruction of AEDs, recognising their life-saving potential.

Beyond these proposals, some MPs pressed for the inclusion of AEDs in emergency preparedness protocols across sectors, including education, sport, and transport. Others stressed the importance of funding for maintenance and pad/battery replacements, ongoing costs that many community groups struggle to cover.

What this means for BHTA members

For BHTA members working across medical devices, community care, and public health, the debate underscored both the urgency and opportunity in this space:

• Policy alignment: the discussion strongly validates the BHTA-led Heart Restart Tax campaign, especially around VAT reform.
• Market demand: there is clear and growing need for accessible, portable, and 24/7 available defibrillator solutions—both for public spaces and workplaces.
• Collaborative opportunity: the call for government-charity collaboration creates space for BHTA members to be key solution providers.
• Equity in healthcare: the debate supports the BHTA’s mission to ensure that health and care solutions reach everyone, not just those with postcode privilege.

This momentum offers a valuable platform for BHTA members to engage with policymakers, contribute to national mapping and training initiatives, and lead on innovation that brings AED access within reach of all communities.

Key recommendations for policymakers:

• Remove VAT on defibrillators and accessories
• Improve national AED registration and accessibility
• Mandate inclusion of AEDs in public planning frameworks
• Enforce regular maintenance standards
• Introduce CPR and AED training in schools and driving tests
• Criminalise vandalism and misuse of AEDs
• Expand public health initiatives to prevent cardiac arrests